323 pipeline articles
FDA Approves Caplyta (lumateperone) for Schizophrenia in Adults
FDA approves Caplyta to treat schizophrenia in adults.
FDA approved Caplyta (lumateperone) for treatment of schizophrenia in adults. The approval was based on two placebo-controlled trials showin…
The FDA approved Caplyta (lumateperone) for treating schizophrenia in adults. It is a once-daily pill that works without needing to adjust t…
FDA Approves IC-GREEN (indocyanine green) for Fluorescence Imaging in Multiple Indications
FDA approves IC-GREEN dye to help surgeons see blood flow and tissues during operations.
The FDA approved IC-GREEN (indocyanine green) for fluorescence imaging of vessels, blood flow, tissue perfusion, extrahepatic biliary ducts,…
The FDA approved IC-GREEN (indocyanine green) to help surgeons see blood vessels, bile ducts, and lymph nodes during certain surgeries. It c…
FDA Approves Mydayis (mixed salts of a single-entity amphetamine) for ADHD in Patients 13 and Older
FDA approves new ADHD drug Mydayis for patients 13 and older.
FDA approved Mydayis, a CNS stimulant, for ADHD in patients 13 years and older. The drug is taken once daily upon awakening and may last up …
The FDA approved Mydayis, a once-daily stimulant for ADHD in people 13 and older. It can last up to 16 hours, which may cause insomnia. This…
FDA Approves Vyvanse (lisdexamfetamine) for Binge Eating Disorder in Adults
FDA approves Vyvanse to treat binge eating disorder in adults.
The FDA approved Vyvanse (lisdexamfetamine) for moderate to severe binge eating disorder (BED) in adults. The recommended starting dose is 3…
The FDA has approved Vyvanse (lisdexamfetamine) for moderate to severe binge eating disorder in adults. It was already approved for ADHD. Th…
FDA Approves Metronidazole Injection for Anaerobic Infections and Prophylaxis
FDA approves new antibiotic for serious anaerobic bacterial infections
The FDA approved Metronidazole Injection for treatment of serious anaerobic infections and for prophylaxis in elective colorectal surgery. I…
The FDA approved Metronidazole Injection USP for serious infections caused by anaerobic bacteria. It treats conditions like abdominal, skin,…
FDA Approves Crysvita (burosumab) for X-Linked Hypophosphatemia and Tumor-Induced Osteomalacia
FDA approves new drug Crysvita for rare bone diseases in children and adults.
FDA approved Crysvita (burosumab) for X-linked hypophosphatemia (XLH) in patients 6 months and older and for tumor-induced osteomalacia (TIO…
The FDA approved Crysvita (burosumab) for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). It is the first treatment th…
FDA Approves Vyvanse (lisdexamfetamine) for Binge Eating Disorder
FDA approves Vyvanse to treat binge eating disorder in adults
FDA approved Vyvanse (lisdexamfetamine) for moderate to severe binge eating disorder (BED) in adults. The approval was based on clinical stu…
The FDA approved Vyvanse for moderate to severe binge eating disorder in adults. It is a stimulant already used for ADHD. This gives patient…
FDA Approves Perjeta (pertuzumab) for HER2-Positive Breast Cancer
FDA approves new drug Perjeta for HER2-positive breast cancer.
The FDA approved Perjeta (pertuzumab) for use in combination with trastuzumab and chemotherapy for HER2-positive metastatic breast cancer an…
The FDA approved Perjeta (pertuzumab) for HER2-positive breast cancer. It is used with other drugs for metastatic, locally advanced, or earl…
FDA Approves Zurzuvae (zuranolone) for Postpartum Depression in Adults
FDA approves new pill for postpartum depression, offering faster relief.
FDA approved Zurzuvae (zuranolone) for postpartum depression (PPD) in adults. It is a GABA-A receptor positive modulator taken once daily fo…
The FDA approved Zurzuvae (zuranolone), a daily pill for postpartum depression. It works quickly over 14 days. This gives new mothers an ora…
FDA Approves Tzield (teplizumab) to Delay Onset of Stage 3 Type 1 Diabetes
FDA approves Tzield to delay type 1 diabetes in high-risk patients
The FDA approved Tzield (teplizumab) to delay the onset of Stage 3 type 1 diabetes in patients aged 1 year and older with Stage 2 disease. T…
The FDA approved Tzield (teplizumab) to delay the onset of stage 3 type 1 diabetes in people aged 1 and older with stage 2 disease. This is …
FDA Approves Ontruzant (trastuzumab-dttb) for HER2-Overexpressing Breast and Gastric Cancers
FDA approves new cancer drug called Ontruzant for certain breast and stomach cancers
Ontruzant (trastuzumab-dttb) is approved for HER2-overexpressing breast cancer and metastatic gastric or gastroesophageal junction adenocarc…
The FDA has approved a new drug called Ontruzant for treating certain breast and stomach cancers. It works for cancers that have too much of…
FDA Approves Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older
The FDA has approved a new drug called Cosentyx for treating a serious skin condition.
The FDA approved Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older who are c…
The FDA approved Cosentyx for moderate to severe plaque psoriasis in adults and children 6 and older. It is a biologic drug that targets inf…
FDA Approves Cosentyx (secukinumab) for Moderate to Severe Hidradenitis Suppurativa in Adults and Pediatric Patients
The FDA approved a new use for the drug Cosentyx to treat a painful skin condition.
The FDA has approved Cosentyx for moderate to severe hidradenitis suppurativa in adults and pediatric patients 12 years and older. This inte…
The FDA has approved Cosentyx for treating moderate to severe hidradenitis suppurativa, a chronic skin condition that causes painful lumps. …
FDA Approves DATSCAN (ioflupane I-123) for Striatal Dopamine Transporter Visualization in Suspected Parkinsonian Syndromes or Dementia with Lewy Bodies
FDA approves new brain imaging drug to help doctors diagnose Parkinson's and similar conditions.
DATSCAN is approved as an adjunct diagnostic for striatal dopamine transporter visualization using SPECT brain imaging in adult patients wit…
FDA approves new brain imaging drug to help doctors diagnose Parkinson's and similar conditions.
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
The FDA approved a drug called Stelara to treat several inflammatory conditions in adults and children.
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
FDA approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in adults an…
FDA Approves Wainua (autoinjector) for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
FDA approves new monthly injection called Wainua for a rare nerve disease in adults.
The FDA approved Wainua, a transthyretin-directed antisense oligonucleotide, for treating polyneuropathy of hereditary transthyretin-mediate…
FDA approves new monthly injection Wainua to treat nerve damage in adults with a rare inherited disease called hereditary transthyretin-medi…
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
The FDA has approved a new drug called Stelara for several inflammatory conditions.
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
The FDA has approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in a…
FDA Approves Itovebi (Itovebi) for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
FDA approves new breast cancer drug Itovebi for a specific type of advanced cancer.
The FDA approved Itovebi in combination with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, HR-positive, H…
A new oral drug, Itovebi, is now FDA-approved for advanced breast cancer with a specific genetic mutation, offering another option when horm…
FDA Approves Dupixent (dupilumab) for Allergic Fungal Rhinosinusitis in Patients with History of Sino-Nasal Surgery
FDA approves Dupixent for treating allergic fungal sinus infections in patients who have had sinus surgery.
Dupixent (dupilumab) has been approved for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosi…
FDA approves Dupixent for allergic fungal sinus infections in adults and children aged 6 and older who have had sinus surgery.
FDA Approves Spravato (esketamine) for Treatment-Resistant Depression and Depressive Symptoms with Acute Suicidal Ideation in Adults
The FDA approved a new nasal spray called Spravato for severe depression.
The FDA approved Spravato (esketamine) for treatment-resistant depression in adults as monotherapy or with an oral antidepressant, and for d…
FDA approved a new nasal spray for severe depression when other treatments fail or when patients face acute suicidal thoughts.
FDA Approves Abreva () for cold sores/fever blisters on the face or lips to shorten healing time and duration of symptoms.
The FDA has approved a new non-prescription drug called Abreva for treating cold sores.
The FDA approved Abreva for treating cold sores/fever blisters on the face or lips to shorten healing time and duration of symptoms such as …
FDA approves new over-the-counter drug Abreva to shorten cold sore healing time and ease painful symptoms like tingling and itching.
FDA Approves Rytelo (telomerase inhibitor oligonucleotide) for transfusion-dependent anemia in low- to intermediate-1 risk MDS
FDA approves new drug called Rytelo for certain blood disorder patients who need frequent transfusions.
Rytelo is approved for adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia…
FDA approves Rytelo to help adults with low-risk blood disorders who need frequent transfusions after other treatments fail.
FDA Approves Danziten (nilotinib) for Adult Patients with Newly Diagnosed or Resistant/Intolerant Ph+ CML
The FDA approved a new drug called Danziten for a type of blood cancer called CML.
Danziten (nilotinib) is approved for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)…
The FDA approved Danziten to treat newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia or cases resistant to prior ima…
FDA Approves Vanflyta (quizartinib) for Newly Diagnosed FLT3-ITD-Positive AML in Adults
FDA approves new drug called Vanflyta for a specific type of blood cancer in adults.
Vanflyta is approved in combination with induction and consolidation chemotherapy, and as maintenance monotherapy, for adult patients with n…
FDA approves Vanflyta to treat acute myeloid leukemia in adults with a specific genetic change that makes the cancer harder to manage.
Prochlorperazine Labeling: Indicated for Severe Nausea/Vomiting and Schizophrenia
The FDA approved a new injection to treat severe nausea and schizophrenia when pills cannot be taken.
FDA labeling for prochlorperazine lists two approved indications: control of severe nausea and vomiting and treatment of schizophrenia. The …
A new FDA-approved injection now treats severe nausea and schizophrenia when patients cannot take pills by mouth.
FDA Approves Concerta (methylphenidate) for ADHD in Patients Aged 6 to 65 Years
The FDA approved a new once-daily ADHD medication called Concerta for people ages 6 to 65.
Concerta (methylphenidate) is approved for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 to 65 years. …
The FDA approved Concerta, a once-daily ADHD medication, for people ages 6 to 65 to help manage symptoms throughout the day with a single do…
FDA Approves Valproic Acid Capsules (valproic acid) for monotherapy and adjunctive therapy of complex partial seizures and absence seizures.
The FDA has approved a new epilepsy drug called Valproic Acid Capsules for treating seizures.
Valproic Acid Capsules were approved for monotherapy and adjunctive therapy of complex partial seizures, and sole and adjunctive therapy of …
The FDA approved Valproic Acid Capsules to treat complex partial and absence seizures in people aged 10 and older.
FDA Approves Rezenopy (naloxone) for Emergency Treatment of Opioid Overdose
FDA approves new nasal spray called Rezenopy for emergency treatment of opioid overdose.
The FDA approved Rezenopy nasal spray for emergency treatment of known or suspected opioid overdose in adult and pediatric patients. It is a…
FDA approves new nasal spray Rezenopy to quickly reverse opioid overdose in adults and children when someone shows slow breathing or is unre…
FDA Approves Cosopt Pf (dorzolamide hydrochloride-timolol maleate ophthalmic solution) for reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension.
The FDA approved a new preservative-free eye drop called Cosopt Pf for treating high eye pressure.
FDA approved Cosopt Pf, a preservative-free ophthalmic solution of dorzolamide hydrochloride and timolol maleate, for reducing elevated intr…
FDA approves new preservative-free eye drop for high eye pressure in patients who don't respond well to beta-blockers.
FDA Approves Onureg (azacitidine) for Continued Treatment of Adult AML Patients in First Remission After Intensive Chemotherapy
The FDA approved a new oral drug called Onureg for certain leukemia patients in remission.
FDA approved Onureg for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission or complete …
FDA approved oral drug Onureg for leukemia patients in remission who cannot complete intensive curative therapy.
FDA Approves Lamotrigine Tablets (lamotrigine) for Epilepsy and Bipolar Disorder Maintenance
The FDA has approved a drug called lamotrigine for epilepsy and bipolar disorder treatment.
Lamotrigine tablets were approved as adjunctive therapy for partial-onset seizures, PGTC seizures, and Lennox-Gastaut syndrome in patients a…
The FDA has approved lamotrigine to help control seizures in children as young as two and maintain mood stability for adults with bipolar di…
FDA Approves Vabysmo (faricimab) for Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Macular Edema Following Retinal Vein Occlusion
The FDA approved a new eye medicine called Vabysmo for several vision conditions.
Vabysmo (faricimab) is approved for neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retina…
FDA approved Vabysmo to treat wet age-related macular degeneration, diabetic macular edema, and swelling after retinal vein occlusion.
FDA Approves Fosfomycin Tromethamine (fosfomycin tromethamine) for Uncomplicated Urinary Tract Infections in Women
FDA approves new single-dose antibiotic for treating bladder infections in women.
Fosfomycin tromethamine granules for oral solution was approved for uncomplicated urinary tract infections (acute cystitis) in women due to …
FDA approves a new single-dose antibiotic for women with bladder infections, offering a convenient one-time treatment option for common urin…
FDA Approves Beyfortus (nirsevimab-alip) for Prevention of RSV Lower Respiratory Tract Disease in Neonates and Infants
FDA approves new drug called Beyfortus to help protect babies and young children from serious RSV illness.
Beyfortus is approved for preventing RSV lower respiratory tract disease in neonates and infants during their first RSV season, and in child…
FDA approves Beyfortus to prevent serious RSV illness in newborns and infants during their first season and children up to 2 years old in th…
FDA Approves Skyclarys for Friedreich's Ataxia in Adults and Adolescents Aged 16 Years and Older
The FDA has approved a new drug called Skyclarys for a rare nerve disorder.
Skyclarys is approved for treating Friedreich's ataxia in adults and adolescents aged 16 years and older. The approval is based on a 48-week…
The FDA has approved Skyclarys to treat Friedreich's ataxia, a rare nerve disorder that causes movement problems in adults and teens aged 16…
FDA Approves Ondansetron Injection, USP (ondansetron hydrochloride) for prevention of nausea and vomiting associated with emetogenic cancer chemotherapy and postoperative nausea/vomiting
FDA approves a new injection to help prevent nausea and vomiting from cancer treatment and surgery.
FDA approved ondansetron injection for prevention of nausea and vomiting associated with emetogenic cancer chemotherapy and postoperative na…
FDA approves new injection to prevent nausea and vomiting from cancer treatment and surgery for children as young as one month old.
FDA Approves Tyvaso (treprostinil) for Pulmonary Arterial Hypertension and Pulmonary Hypertension Associated with Interstitial Lung Disease
FDA approves new inhaled drug called Tyvaso for two serious lung conditions
The FDA approved Tyvaso (treprostinil) for pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with int…
FDA approves new inhaled drug Tyvaso to help adults with serious lung conditions improve their ability to exercise and do daily activities.
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart in certain adults.
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes tablet now helps control blood sugar while also lowering the risk of heart failure hospitalization for adults with heart dise…
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
FDA approves a new pill for type 2 diabetes that also helps protect the heart.
The FDA has approved dapagliflozin tablets for two indications in adults with type 2 diabetes mellitus: to improve glycemic control and to r…
A new FDA-approved pill for type 2 diabetes now helps lower blood sugar while also reducing the risk of hospitalization for heart failure.
FDA Approves Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets for Type 2 Diabetes and Related Risks
FDA approves a new once-daily pill for type 2 diabetes that may also help protect the heart and kidneys.
The FDA has approved dapagliflozin and metformin hydrochloride extended-release tablets as an adjunct to diet and exercise to improve glycem…
A new once-daily pill for type 2 diabetes may protect the heart and kidneys from serious problems like heart attacks and worsening kidney di…
FDA Approves Cefepime for Injection and Dextrose Injection (cefepime) for Moderate to Severe Pneumonia and Other Infections
The FDA approved a new ready-to-use version of an antibiotic called cefepime for serious infections.
The FDA approved cefepime in a dextrose injection formulation for intravenous treatment of moderate to severe pneumonia, febrile neutropenia…
The FDA approved a ready-to-use antibiotic for serious infections like pneumonia and urinary tract infections in hospitalized patients.
FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for PSMA-positive metastatic castration-resistant prostate cancer.
FDA approves a new treatment for advanced prostate cancer called Pluvicto.
The FDA has approved Pluvicto, a radioligand therapeutic agent, for the treatment of adult patients with PSMA-positive metastatic castration…
FDA approves Pluvicto, a targeted radiation therapy for advanced prostate cancer that has spread and stopped responding to standard hormone …
FDA Approves Levetiracetam for Partial-Onset, Myoclonic, and Primary Generalized Tonic-Clonic Seizures
FDA approves a seizure medicine called levetiracetam for children and adults.
Levetiracetam is approved for the treatment of partial-onset seizures in patients 1 month and older, and as adjunctive therapy for myoclonic…
The FDA now approves levetiracetam for children as young as one month and adults to treat specific seizure types.
FDA Approves Ingrezza Sprinkle (valbenazine) for Tardive Dyskinesia and Chorea Associated with Huntington’s Disease.
FDA approves a new sprinkle version of Ingrezza for two movement disorders.
The FDA has approved Ingrezza Sprinkle, a VMAT2 inhibitor, for the treatment of adults with tardive dyskinesia and chorea associated with Hu…
FDA approves sprinkle form of Ingrezza to treat involuntary movements in adults with tardive dyskinesia or Huntington's disease chorea.
FDA Approves Ondansetron Injection, USP (ondansetron hydrochloride) for Prevention of Chemotherapy-Induced and Postoperative Nausea/Vomiting
FDA approves a new preservative-free injection to prevent nausea and vomiting from chemotherapy and surgery.
FDA approved ondansetron injection for prevention of nausea/vomiting associated with emetogenic cancer chemotherapy and postoperative nausea…
FDA approves a new preservative-free injection to prevent nausea and vomiting from chemotherapy and surgery.
FDA Approves Gabapentin Capsules (gabapentin) for Postherpetic Neuralgia and Partial Onset Seizures
FDA approves a new generic version of the drug gabapentin for nerve pain and seizures.
The FDA has approved Gabapentin Capsules, USP for the management of postherpetic neuralgia in adults and as adjunctive therapy for partial o…
FDA approves a new generic gabapentin capsule for nerve pain and seizures, offering patients another low-cost treatment option alongside exi…
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk and Improve Glycemic Control in Adults with Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart in certain adults.
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus a…
A new diabetes drug is approved to lower blood sugar and cut the risk of heart failure hospitalization in adults with type 2 diabetes and he…
FDA Approves Dapagliflozin for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart from failure.
The FDA has approved dapagliflozin to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established ca…
FDA approves a diabetes pill that lowers blood sugar and reduces heart failure hospitalization for adults with type 2 diabetes and heart ris…
FDA Approves Dapagliflozin for Reducing Heart Failure Hospitalization Risk and Improving Glycemic Control in Adults with Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart.
The FDA has approved dapagliflozin to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and estab…
A new diabetes drug now helps lower blood sugar while also reducing the risk of heart failure hospitalization for adults with heart disease …
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
FDA approves a new diabetes pill that also helps protect the heart.
The FDA has approved dapagliflozin tablets for two indications: to improve glycemic control in adults with type 2 diabetes mellitus, and to …
A new daily diabetes pill now approved by the FDA helps lower blood sugar and reduces the risk of heart failure hospitalization for adults w…
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
FDA approves a diabetes pill that also helps protect the heart from failure.
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes pill approved by the FDA also lowers the risk of hospitalization for heart failure in adults with type 2 diabetes.
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
FDA approves a diabetes drug that also helps lower the risk of heart failure.
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes pill now helps lower blood sugar and reduces the risk of hospitalization for heart failure in adults with type 2 diabetes.
FDA Approves Keytruda (pembrolizumab) for Treatment of Unresectable or Metastatic Melanoma
FDA approves new drug Keytruda for advanced skin cancer.
The FDA has approved Keytruda, a PD-1-blocking antibody, for the treatment of patients with unresectable or metastatic melanoma. This approv…
FDA approves Keytruda to treat advanced skin cancer that cannot be removed by surgery or has spread to other parts of the body.
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk in Adults with Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart.
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus a…
A new diabetes drug now protects the heart by lowering hospitalization risks for adults with type 2 diabetes and existing heart disease.
FDA Approves Valproic Acid Oral Solution (valproic acid) for Monotherapy and Adjunctive Therapy of Complex Partial and Absence Seizures
The FDA has approved a liquid form of an existing epilepsy and migraine prevention medicine.
The FDA has approved valproic acid oral solution for monotherapy and adjunctive therapy of complex partial seizures, and as sole and adjunct…
The FDA approved a liquid version of valproic acid, an established epilepsy and migraine medicine, offering an easier swallowing option for …
FDA Approves Valproic Acid Oral Solution (valproic acid) for Monotherapy and Adjunctive Therapy of Complex Partial and Absence Seizures
FDA approves a liquid form of an existing epilepsy medicine called valproic acid.
The FDA has approved valproic acid oral solution for monotherapy and adjunctive therapy of complex partial seizures, and as sole and adjunct…
FDA approves liquid valproic acid for epilepsy patients 10 and older who struggle to swallow pills or need flexible dosing.
FDA Approves Valproic Acid Oral Solution (valproic acid) for Complex Partial and Absence Seizures.
The FDA has approved a liquid form of an older seizure medicine called valproic acid.
Valproic acid oral solution is approved as monotherapy and adjunctive therapy for complex partial seizures and for simple and complex absenc…
The FDA approved a liquid version of valproic acid to help adults and children over 10 manage complex partial and absence seizures when pill…
FDA Approves Eylea HD (aflibercept) for nAMD, DME, Diabetic Retinopathy, and Macular Edema Following RVO
FDA approves a new, higher-dose version of the eye medicine Eylea.
The FDA has approved Eylea HD, a VEGF inhibitor, for the treatment of neovascular age-related macular degeneration, diabetic macular edema, …
FDA approves higher-dose Eylea to treat four eye conditions that damage the retina and threaten vision, potentially reducing how often patie…
FDA Approves Nintedanib Capsules (nintedanib esylate) for Idiopathic Pulmonary Fibrosis and Progressive Fibrosing ILDs
FDA approves a new drug to treat two types of progressive, scarring lung diseases.
The FDA has approved nintedanib capsules for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and for adults with chronic fi…
FDA approves new drug to treat two types of progressive, scarring lung diseases that make lungs stiff and hard to breathe.
FDA Approves Nintedanib Capsules (nintedanib esylate) for Idiopathic Pulmonary Fibrosis and Progressive Fibrosing ILDs
FDA approves a new drug to treat two serious, scarring lung diseases in adults.
The FDA has approved nintedanib capsules for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and for adults with chronic fi…
FDA approves new drug nintedanib to treat two serious, scarring lung diseases in adults with progressive conditions.
FDA Approves FOUNDAYO (orforglipron) for chronic weight management in adults with obesity or overweight with comorbidities.
The FDA has approved a new daily pill called FOUNDAYO to help adults manage their weight.
The FDA has approved FOUNDAYO (orforglipron), an oral GLP-1 receptor agonist, for chronic weight management in adults with obesity or overwe…
FDA approves new daily pill FOUNDAYO for adults to manage weight alongside diet and exercise.
FDA Approves Kesimpta (ofatumumab) for Relapsing Forms of Multiple Sclerosis in Adults
The FDA approved a new monthly self-injection drug for multiple sclerosis.
The FDA has approved Kesimpta, a CD20-directed cytolytic antibody, for the treatment of relapsing forms of multiple sclerosis in adults. The…
The FDA approved Kesimpta, a new monthly self-injection for adults with relapsing forms of multiple sclerosis.
FDA Approves Vafseo (vadadustat) for Anemia Due to Chronic Kidney Disease in Adults on Dialysis
FDA approves a new oral pill for anemia in adults with chronic kidney disease on dialysis.
The FDA has approved Vafseo (vadadustat) for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysi…
FDA approves a new oral pill for anemia in adults with chronic kidney disease on dialysis, offering a non-transfusion option for those treat…
FDA Approves Zynyz (retifanlimab-dlwr) for Metastatic Anal Canal Cancer and Merkel Cell Carcinoma
FDA approves new drug Zynyz for two rare and aggressive types of cancer.
The FDA has approved Zynyz, a PD-1 blocking antibody, for two indications: first-line treatment of inoperable locally recurrent or metastati…
FDA approves new drug Zynyz to treat two rare and aggressive cancers: advanced anal cancer and Merkel cell carcinoma.
FDA Approves Lamotrigine for Adjunctive Therapy in Epilepsy and Maintenance in Bipolar I Disorder
FDA approves lamotrigine, a medicine for epilepsy and bipolar disorder.
Lamotrigine is approved for adjunctive therapy of partial-onset seizures, PGTC seizures, and seizures of Lennox-Gastaut syndrome in patients…
The FDA officially approves lamotrigine for epilepsy and bipolar disorder, confirming a long-used treatment option for adults and children a…
FDA Approves Bupropion Hydrochloride Extended-Release Tablets (SR) (bupropion) for Major Depressive Disorder
FDA approves a new, longer-acting version of the antidepressant bupropion.
The FDA has approved Bupropion Hydrochloride Extended-Release Tablets (SR) for the treatment of major depressive disorder (MDD). Efficacy wa…
A new extended-release antidepressant now helps adults manage depression for up to 44 weeks following initial treatment.
FDA Approves Byooviz (ranibizumab) for Neovascular AMD, Macular Edema Following RVO, and Myopic CNV
FDA approves a new eye medicine called Byooviz for three conditions that can cause vision loss.
The FDA has approved Byooviz, a VEGF inhibitor, for intravitreal injection to treat neovascular age-related macular degeneration, macular ed…
FDA approves Byooviz to treat three eye conditions causing vision loss from leaky blood vessels in the retina.
FDA Approves Focinvez (fosaprepitant) for Prevention of Chemotherapy-Induced Nausea and Vomiting
FDA approves a new intravenous drug to help prevent nausea and vomiting from chemotherapy.
The FDA has approved Focinvez, a substance P/NK1 receptor antagonist, for the prevention of acute and delayed nausea and vomiting associated…
FDA approves new IV drug to prevent severe nausea and vomiting from chemotherapy in adults and children 6 months and older.
FDA Approves Depakote Sprinkle Capsules (valproate) for Monotherapy and Adjunctive Therapy of Complex Partial and Absence Seizures.
FDA approves a new sprinkle capsule form of the epilepsy drug Depakote.
The FDA approved Depakote Sprinkle Capsules (valproate) for monotherapy and adjunctive therapy of complex partial seizures and simple and co…
FDA approves a sprinkle capsule form of Depakote that patients can open and mix with soft food to help those who struggle to swallow pills.
FDA Approves Depakote ER (divalproex sodium) for Acute Manic or Mixed Episodes in Bipolar Disorder
FDA approves a new once-daily pill for treating manic episodes in bipolar disorder.
The FDA has approved Depakote ER, an extended-release valproate, for the acute treatment of manic or mixed episodes associated with bipolar …
FDA approves a new once-daily pill for short-term treatment of severe manic episodes in adults with bipolar I disorder.
FDA Approves Valproate Sodium Injection (valproate sodium) for IV Use in Complex Partial and Absence Seizures
FDA approves an injectable version of an existing seizure medicine for short-term use.
The FDA approved Valproate Sodium Injection as an intravenous alternative when oral valproate is temporarily not feasible. It is indicated f…
FDA approves an injectable seizure medicine for short-term use when patients can't swallow pills due to surgery or stomach issues.
FDA Approves Depakote (divalproex sodium) for Manic Episodes Associated with Bipolar Disorder
FDA approves Depakote for treating manic episodes in bipolar disorder.
The FDA approved Depakote (divalproex sodium) for the treatment of manic episodes associated with bipolar disorder. The approval was based o…
FDA approves Depakote for treating manic episodes in hospitalized adults with bipolar disorder, offering doctors a new option for managing a…
FDA Approves Xarelto (rivaroxaban) for multiple indications including stroke prevention in nonvalvular atrial fibrillation and treatment of VTE.
FDA approves a new blood thinner called Xarelto for several heart and clot conditions.
The FDA approved rivaroxaban (Xarelto), a factor Xa inhibitor, for multiple indications including reducing stroke risk in nonvalvular atrial…
FDA approves new blood thinner Xarelto to prevent dangerous clots in heart conditions, deep vein issues, and after major surgeries.
FDA Approves Children's Zyrtec Allergy (cetirizine) for Symptoms of Upper Respiratory Allergies
FDA approves a chewable allergy medicine for children called Children's Zyrtec Allergy.
The FDA approved Children's Zyrtec Allergy (cetirizine) for temporarily relieving symptoms of hay fever or other upper respiratory allergies…
FDA approves chewable allergy medicine for kids as young as 2 to help with runny nose, sneezing, and itchy eyes from hay fever.
FDA Approves Ringer's In Plastic Container (Ringer's solution) for parenteral replacement of extracellular fluid and electrolyte losses.
The FDA approved a new intravenous fluid called Ringer's In Plastic Container.
The FDA approved Ringer's In Plastic Container for parenteral replacement of extracellular losses of fluid and electrolytes, as required by …
FDA approves new IV fluid to replace lost water and minerals like sodium and potassium for patients needing hydration after surgery or from …
FDA Approves Xarelto (rivaroxaban) for Thromboprophylaxis in Pediatric Patients After Fontan Procedure
FDA approves Xarelto to help prevent blood clots in children with certain heart conditions.
The FDA approved rivaroxaban (Xarelto) for thromboprophylaxis in pediatric patients aged 2 years and older with congenital heart disease who…
FDA approves Xarelto to prevent dangerous blood clots in children aged 2 and older born with heart defects who have had Fontan surgery.
FDA Approves Marinol (dronabinol) for AIDS-Related Anorexia and Chemotherapy-Induced Nausea/Vomiting
FDA approves a new drug called Marinol to help with AIDS-related weight loss and chemotherapy nausea.
The FDA has approved Marinol (dronabinol) for two indications in adults: anorexia associated with weight loss in patients with AIDS, and nau…
The FDA approved Marinol to treat AIDS-related weight loss and severe chemotherapy nausea that standard treatments couldn't control.
FDA Approves Winrevair for Pulmonary Arterial Hypertension (PAH) in Adults
FDA approves a new treatment for a serious lung condition called pulmonary arterial hypertension.
The FDA has approved Winrevair for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise capac…
A new FDA-approved injection helps adults with pulmonary arterial hypertension exercise longer, improve daily life, and lower the risk of ho…
FDA Approves Elrexfio for Relapsed or Refractory Multiple Myeloma After Four Prior Lines of Therapy
The FDA approved a new treatment for a type of blood cancer called multiple myeloma.
The FDA has approved Elrexfio, a bispecific BCMA-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myelom…
A new FDA-approved treatment helps shrink multiple myeloma in patients who have already tried at least four other therapies.
FDA Approves Methylphenidate Hydrochloride Extended-Release Tablets for ADHD and Narcolepsy
The FDA has approved a new, longer-acting generic version of a common ADHD and narcolepsy medication.
The FDA has approved methylphenidate hydrochloride extended-release tablets for the treatment of Attention Deficit Hyperactivity Disorder (A…
The FDA approved a new generic ADHD and narcolepsy medicine that works for about 8 hours, offering a longer-lasting option for patients 6 ye…
FDA Approves Krazati (adagrasib) for KRAS G12C-Mutated NSCLC and in Combination for Colorectal Cancer
FDA approves a new targeted cancer drug called Krazati for lung and colorectal cancers.
The FDA has approved Krazati as a single agent for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC after at least…
FDA approves Krazati, a new targeted drug for lung and colorectal cancers with a specific genetic change after other treatments fail.
Phase 4 study of evolocumab safety and tolerability in renal transplant recipients
Can a new cholesterol drug help kidney transplant patients without causing harm?
This Phase 4 study evaluated the safety and tolerability of evolocumab, a PCSK-9 inhibitor, in renal transplant recipients at three hospital…
A new cholesterol injection kept kidney transplant patients safe for over two years without serious side effects, offering a potential alter…
Dimethyl fumarate with slow titration improves treatment satisfaction and quality of life in Iranian MS patients
Oral Pill Beats Shots for MS Patients
A 12-month, multicenter, phase 4 observational study of 645 Iranian patients with relapsing-remitting multiple sclerosis initiating dimethyl…
An oral pill for multiple sclerosis improves sleep and mood while boosting patient satisfaction compared to monthly injections.
Oral polio vaccine and behavioral information versus no vaccine in adults over 50 years of age
Old Vaccine Might Help Stop COVID
This Phase 4 randomized trial evaluated the effect of oral polio vaccine plus behavioral information compared with no vaccine in 3,729 perso…
An old polio vaccine pill given to adults in Guinea-Bissau might protect older people from severe coronavirus illness and death.
Liposomal bupivacaine, nerve blocks compared to lidocaine for skin graft donor site pain in burn patients
What's the best way to ease pain after skin graft surgery for burn patients?
A two-phase study (RCT and prospective cohort) in 74 burn patients with <20% TBSA burns compared liposomal bupivacaine injection and preoper…
Burn patients with minor injuries face intense donor site pain after skin graft surgery, but doctors haven't yet reported which numbing meth…
Phase 4 trial compares pioglitazone versus dapagliflozin add-on in type 2 diabetes
Trial compares two diabetes drug combinations but results are not yet available
A phase 4 randomized controlled trial in South Korea enrolled 133 participants with type 2 diabetes inadequately controlled by DPP-4 inhibit…
A completed trial in South Korea compared two three-drug combinations for type 2 diabetes, but results on blood sugar control are not yet av…
Digital albuterol system feasibility studied in 333 asthma patients with suboptimal control
Can a smart inhaler help people with uncontrolled asthma breathe easier?
A phase 4, open-label, multicenter feasibility study randomized 333 participants aged 13+ with suboptimal asthma control to either the Albut…
A new smart inhaler system tested for 12 weeks to see if it helps people with uncontrolled asthma breathe easier, but results are not yet av…
Phase 4 trial compares LPV/r plus raltegravir versus LPV/r plus N(t)RTIs for HIV after first-line failure
Study compares two HIV treatment strategies after first-line therapy fails
A phase 4 randomized controlled trial enrolled 558 HIV-infected subjects who had virologically failed first-line NNRTI-based therapy. The st…
A completed Phase 4 trial compared two HIV treatment strategies after first-line therapy fails, but results for viral suppression and safety…
Phase 4 study evaluates nitroglycerin's effects on stroke volume in 21 AHF patients
Can a common heart drug help people with acute heart failure breathe easier?
A Phase 4 study enrolled 21 patients with acute heart failure to evaluate the effects of nitroglycerin on stroke volume. The study aimed to …
Nitroglycerin may help acute heart failure patients pump more blood and flush out fluid to ease breathing in the critical early hours of tre…
Atorvastatin evaluated for dyslipidemia in children with steroid-sensitive nephrotic syndrome
Can a common cholesterol drug protect children's hearts and kidneys from a hidden danger?
A quasi-experimental study of 100 children aged 8-18 years with steroid-sensitive nephrotic syndrome and dyslipidemia evaluated the effectiv…
A common cholesterol drug called atorvastatin may help children with kidney disease reach safer heart and blood fat levels when diet alone i…
Vedolizumab with Adalimumab or Ustekinumab Studied for Crohn's Endoscopic Response
Can New Drug Combinations Offer Hope for Crohn's Disease Sufferers?
Phase 4 trial investigates vedolizumab with adalimumab or ustekinumab in Crohn's. Primary endpoint: endoscopic response at 26 weeks.
Adults with moderate to severe Crohn's disease may find new relief by combining vedolizumab with adalimumab or ustekinumab before continuing…
Ketamine in Orthopedic Trauma: Potential to Reduce Pain and Opioid Use
Could Ketamine Be the Key to Easing Pain and Healing Minds After Surgery?
This Phase 4 trial investigates ketamine's efficacy in reducing postoperative pain and opioid use in orthopedic trauma patients. Primary out…
A new trial tests if giving ketamine during orthopedic surgery reduces pain, opioid needs, and symptoms of depression and PTSD compared to s…
Lanadelumab reduced attacks in Chinese adults with hereditary angioedema over six months
Imagine waking up with severe swelling in your throat. It feels like you cannot breathe. This is what hereditary angioedema feels like for many people.
This open-label study evaluated safety and efficacy of subcutaneous lanadelumab in patients with hereditary angioedema in China. Investigato…
This rare condition causes painful swelling under the skin.
Semaglutide high dose for weight reduction in people with Type 2 Diabetes
New drug helps obese diabetics lose weight and control sugar
This randomized controlled trial in 512 people with excess weight and Type 2 Diabetes compared high-dose semaglutide to placebo and lower do…
New research shows a specific injection helps people with obesity and diabetes lose weight and control their blood sugar levels better than …
Metformin, fluvoxamine, or ivermectin for non-hospitalized COVID-19 adults in a Phase 3 trial
Metformin Cuts Long Covid Risk by 40%
This randomized controlled trial in 1323 non-hospitalized adults with SARS-CoV-2 infection evaluated metformin, fluvoxamine, or ivermectin v…
A common diabetes pill taken early in Covid infection cuts the odds of developing long-term symptoms by 40%, offering new hope for millions.
Pembrolizumab adjuvant therapy trial for hepatocellular carcinoma recurrence-free survival
Pembrolizumab May Cut Liver Cancer Return After Surgery
This is a Phase 3 randomized controlled trial in 959 participants with hepatocellular carcinoma who had a complete radiological response aft…
After liver surgery, pembrolizumab may help keep hepatocellular carcinoma from returning, offering new hope for patients with complete tumor…
Arbaclofen Phase 3 Trials Establish Clinically Meaningful Change Thresholds in Fragile X Syndrome
New Rules for Measuring Behavior Change in Fragile X
A review of two Phase 3 trials in 278 individuals with Fragile X Syndrome (aged 5-50 years) established clinically meaningful change thresho…
Imagine a parent watching their child struggle with daily routines.
Immunoembolization shows lower disease control than FOCUS trial in liver-dominant metastatic uveal melanoma.
Eye Cancer in Liver: New Therapy Extends Life Even When Tumors Grow
This single-center retrospective analysis evaluated immunoembolization (IE) in 43 patients with liver-dominant metastatic uveal melanoma. Th…
A new liver treatment for eye cancer patients may help them live longer, even if it does not shrink tumors as much as expected.
Trofinetide treatment shows symptom improvement in Rett syndrome observational study
</think>
This 12-month observational study of 55 children with Rett or MECP2-related disorders found 75.9% experienced some symptom improvement with …
Real-World Data Shows Rett Drug Helps Most
Tirzepatide MTD Demonstrates Cost-Effectiveness Versus Semaglutide MTD in Obesity Simulation Modeling Study
Tirzepatide Saves Money and Health Over Semaglutide
This simulation modeling study using Phase-3 trial data evaluated tirzepatide versus semaglutide in individuals with obesity or overweight w…
Imagine standing in a doctor's office, facing a choice between two powerful weight-loss medicines.
Feasibility of Trans-aqueduct Access to Third Ventricle via Minimally Invasive Techniques in MRI and Cadaveric Specimens
New Pathway Opens Doors to Deep Brain Therapy
This pre-clinical feasibility study evaluated trans-aqueduct access to the third ventricle using human MRI datasets (n=16) and cadaveric spe…
Scientists found a small route to treat brain conditions without major surgery.
Single COVID-19 vaccine dose boosts antibody levels in individuals with prior SARS-CoV-2 acquisition
One Dose Could Be Enough If You Had COVID First
A cross-protocol analysis of six phase 3 trials in individuals with and without prior SARS-CoV-2 acquisition found that a single COVID-19 va…
People who had COVID before getting vaccinated often need only one shot to reach antibody levels matching two doses for others.
SCOPE platform predicts outcomes for metastatic colorectal and pancreatic cancers using organoid screening.
A Lab-Built Tumor Test May Predict If Cancer Drugs Will Work
This preclinical platform development study utilized a machine learning system integrating patient-derived organoids and clinical data to pr…
A platform called SCOPE uses tiny lab-grown copies of a patient's tumor to predict — before a large trial even starts — whether a cancer dru…
Add-on atogepant 60 mg daily reduced monthly migraine days in chronic migraine patients on stable onabotulinumtoxinA.
Adding atogepant to botulinum toxin reduced migraine days in a small study
This Phase 3, multicenter, 24-week, open-label, single arm study evaluated add-on atogepant 60 mg once daily in 75 participants with chronic…
Adding atogepant to botulinum toxin cut migraine days by over 50% for 62% of patients in a study, with most finding it safe and well-tolerat…
Bempedoic acid 180 mg/day reduces LDL-C in Japanese patients with hypercholesterolemia over 52 weeks.
New Cholesterol Option Works Well for Statin Intolerant Patients
This multicenter, open-label, single-arm Phase 3 study evaluated bempedoic acid 180 mg/day in 130 Japanese patients with hypercholesterolemi…
A new cholesterol drug safely lowers bad cholesterol for one year in patients who cannot take standard statin medications.
Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment
Study checks how well pain scores track joint damage in psoriatic arthritis patients
Phase III randomized clinical trials in 1,405 participants with psoriatic arthritis evaluated guselkumab treatment through week 100. The stu…
Pain scores for psoriatic arthritis strongly predict long-term joint damage, giving doctors clear numbers to track real progress and adjust …
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in Chinese adults with advanced biliary tract carcinoma
Could adding pembrolizumab help Chinese adults live longer with advanced biliary tract carcinoma?
This phase 3 randomized controlled trial enrolled 158 Chinese adults with advanced or unresectable biliary tract carcinoma. The study compar…
A completed study in China compared adding pembrolizumab to chemotherapy for advanced bile duct cancer, tracking how long 158 adults survive…
Corrective re-analysis suggests Lp(a) reduction accounts for 57-70% of PCSK9 inhibitor benefit in ASCVD.
Re-analysis suggests most PCSK9 inhibitor benefit comes from lowering Lp(a)
This Phase 3 corrective re-analysis of cardiovascular outcomes trial data in secondary prevention populations with ASCVD evaluated the role …
Researchers re-analyzed data from Phase 3 trials of alirocumab and evolocumab in patients with atherosclerotic cardiovascular disease. They …
MRI outcomes show weak association with disability in primary progressive multiple sclerosis patients
MRI results show weak connection to disability changes in progressive multiple sclerosis
This Phase 3 trial secondary analysis evaluated 943 patients with primary progressive multiple sclerosis treated with glatiramer acetate ove…
MRI scans show weak links to disability changes in progressive multiple sclerosis, challenging their use as reliable trial endpoints for thi…
Talazoparib plus enzalutamide shows high probability of benefit in Japanese mCRPC subgroup
New Math Brings Hope to Japanese Men With Advanced Prostate Cancer
A Bayesian reanalysis of phase III trial data in 116 Japanese patients with metastatic castration-resistant prostate cancer found a 98% prob…
New math suggests a two-drug combo likely works for Japanese men with advanced prostate cancer, even when original trial numbers looked unce…
Quadrivalent influenza vaccine shows immunogenicity and safety in Indian population aged 6 months and older
New flu vaccine data shows strong immune response in Indian children and adults
An open-label phase III study of 401 participants aged 6 months and older across five Indian sites evaluated a quadrivalent inactivated spli…
A new flu vaccine study in India shows strong immune protection for children and adults against all four virus strains with no serious side …
Review finds nivolumab improves survival across multiple cancers, highlights access and sequencing challenges
Nivolumab improves survival for many cancers, but access and treatment planning remain challenges
A global review of nivolumab in patients with various malignancies reports better survival rates and subsequent regulatory approvals. The ev…
Nivolumab helps many cancer patients live longer, yet doctors still face hurdles in getting everyone the care they need.
Real-world study shows lenalidomide-dexamethasone yields 22.9-month PFS in transplant-ineligible myeloma
Real-world study shows lenalidomide treatment outcomes for older multiple myeloma patients
A prospective, non-interventional study of 168 transplant-ineligible NDMM patients in Germany found median PFS of 22.9 months and OS of 58.1…
Real-world data shows lenalidomide plus low-dose dexamethasone keeps older multiple myeloma patients disease-free for nearly two years while…
Phase 3 trial of TMB-001 topical ointment for congenital ichthyosis reports no efficacy results
Phase 3 trial tests topical ointment TMB-001 for congenital ichthyosis
A phase 3, randomized, double-blind, vehicle-controlled trial in 153 subjects with congenital ichthyosis (RXLI or ARCI subtypes) evaluated T…
A new ointment for congenital ichthyosis is being tested in a rigorous study to see if it can safely improve dry, scaly skin symptoms.
8-week glecaprevir/pibrentasvir shows 96.2% SVR12 in acute HCV treatment-naïve adults
Can a short treatment course cure most cases of acute hepatitis C?
A single-arm Phase IIIb study of 286 treatment-naïve adults with acute HCV found 96.2% achieved SVR12 with an 8-week glecaprevir/pibrentasvi…
A short eight-week treatment cured 96.2% of adults with new hepatitis C infections, with a perfect success rate for those who completed the …
Phase 3 trial of oral PCSK9 inhibitor enlicitide in hypercholesterolemia reports no results
Can a new pill lower cholesterol as well as existing drugs?
A completed phase 3 randomized controlled trial in 301 adults with hypercholesterolemia compared oral PCSK9 inhibitor enlicitide to ezetimib…
A new cholesterol pill called enlicitide finished its final trial, but the results showing how well it lowers bad cholesterol and its safety…
Planned trial compares injectable antipsychotics to usual care for psychosis with stimulant use
Hong Kong trial planned to test antipsychotic injections for substance use with psychosis
A trial record describes a planned phase 2/3 study of 165 individuals in Hong Kong with substance use disorders and psychosis. The study wil…
Hong Kong researchers plan a trial to test long-acting antipsychotic injections for people with substance use disorders and psychosis.
Phase 3 trial of pembrolizumab plus chemo for advanced biliary tract carcinoma posts results
Can adding pembrolizumab to standard chemo help people with advanced bile duct cancer?
A phase 3 randomized controlled trial in 1,069 participants with advanced biliary tract carcinoma compared first-line pembrolizumab plus gem…
A large trial of adding immunotherapy to standard chemo for advanced bile duct cancer is complete, but the results showing if patients live …
Phase 3 trial of pembrolizumab versus placebo after surgery for Stage IB-IIIA NSCLC posts results
Can a drug help keep lung cancer from returning after surgery?
A Phase 3 randomized controlled trial in 1177 participants with resected Stage IB-IIIA NSCLC compared adjuvant pembrolizumab to placebo. The…
A large trial tested whether the drug pembrolizumab helps keep early-stage lung cancer from returning after surgery for over 1,100 patients.
Phase 3 trial of navitoclax plus ruxolitinib versus ruxolitinib alone in myelofibrosis posts results
Phase 3 trial tests navitoclax with ruxolitinib for myelofibrosis spleen volume
A phase 3 randomized controlled trial in 252 adults with myelofibrosis compared navitoclax plus ruxolitinib to ruxolitinib plus placebo. The…
A new drug combination aims to shrink painful enlarged spleens in myelofibrosis patients, but results from this large global trial are not y…
Topical milrinone or nitroglycerin studied for internal mammary artery flow in CABG patients
Small study tests topical drugs on artery grafts during heart bypass surgery
A phase 3 randomized trial in 46 patients undergoing elective CABG compared topical milrinone, nitroglycerin, or normal saline applied to th…
A small study tested topical drugs on artery grafts during heart bypass surgery, measuring blood flow changes in 46 patients over just 12 mi…
Phase 3 trial compares switch to doravirine/islatravir versus continuing bictegravir/FTC/TAF in HIV-1
Phase 3 trial compares two HIV drug regimens for people already virologically suppressed.
A phase 3 randomized controlled trial enrolled 643 virologically suppressed adults with HIV-1 to compare switching to doravirine/islatravir …
People with HIV already on effective treatment can safely switch to a new two-drug pill without losing virus control, according to a complet…
Lung cancer trial patients show disparities in optional biospecimen study participation
Who gets left out when cancer patients are asked to donate tissue for research?
An observational analysis of 3017 patients in two phase 3 lung cancer trials found 89% agreed to participate in optional biospecimen studies…
Women and racial minorities in lung cancer trials are less likely to donate tissue samples, risking that future research misses the very peo…
Damoctocog alfa pegol shows safety and maintained bleed protection in children with severe haemophilia A
Study finds haemophilia drug safe and effective in children over six months
A phase 3, open-label, single-arm study of 35 previously treated children aged 7 to <12 years with severe haemophilia A found no adverse eve…
A haemophilia drug prevented bleeds in children aged 7 to under 12, with no severe side effects and no one stopping treatment due to bad rea…
Phase 3 trial of damoctocog alfa pegol in previously treated children with severe haemophilia A
Phase 3 trial studies new treatment for severe haemophilia A in children
A phase 3 clinical trial evaluated damoctocog alfa pegol in previously treated children aged 7 to 12 years with severe haemophilia A. No res…
A new treatment for severe haemophilia A in children aged 7 to 12 is being tested in a Phase 3 trial to check its safety and effectiveness.
Phase III trial tests TTFields plus standard therapy for stage 4 NSCLC after platinum failure
Can adding electric fields to standard treatment help people with advanced lung cancer?
A prospective, randomized phase III trial in 291 patients with stage 4 NSCLC after platinum progression compared TTFields plus standard ther…
Doctors are testing if adding a wearable electric field device to standard drugs helps people with advanced lung cancer live longer after ch…
Phase 3 trial compares bimekizumab to placebo and ustekinumab for moderate to severe plaque psoriasis
Can a new psoriasis drug outperform an established treatment?
A phase 3 randomized controlled trial enrolled 567 adults with moderate to severe chronic plaque psoriasis to compare bimekizumab against pl…
A new psoriasis drug called bimekizumab is being tested against existing treatments in a major trial involving 567 adults to see if it helps…
Phase 3 trial compares pembrolizumab with or without lenvatinib in PD-L1+ recurrent/metastatic HNSCC
Phase 3 trial tests pembrolizumab with or without lenvatinib for advanced head and neck cancer
A phase 3 randomized controlled trial enrolled 511 patients with PD-L1 selected recurrent or metastatic head and neck squamous cell carcinom…
A completed Phase 3 trial tested pembrolizumab with or without lenvatinib for advanced head and neck cancer, but detailed results are not ye…
Phase III trial compares tisagenlecleucel to standard transplant in relapsed aggressive B-cell NHL
Can a one-time cell therapy beat standard treatment for aggressive lymphoma?
This randomized, open-label, multicenter phase III trial enrolled 322 adults with aggressive B-cell NHL relapsed/refractory within 1 year of…
A major trial compares one-time CAR-T cell therapy against standard chemo and stem cell transplant for aggressive lymphoma that returns quic…
Pink vs. white inhaler actuators studied for asthma symptom perception in crossover trial
Study compares pink and white asthma inhalers for how patients perceive symptoms
A phase IIIb randomized, double-blind, crossover trial in 78 adults with moderate to severe asthma compared identical beclomethasone/formote…
Asthma patients tried identical inhalers in pink or white to see if color changed how they perceived their symptoms and which device they pr…
Phase 3 trial of bimekizumab versus placebo in 435 adults with moderate to severe plaque psoriasis
Can a new drug help people with moderate to severe plaque psoriasis?
A phase 3 randomized controlled trial evaluated bimekizumab versus placebo in 435 adults with moderate to severe chronic plaque psoriasis. T…
A new drug tested in a large study aims to help clear skin for people with moderate to severe plaque psoriasis.
Phase 3 trial of low-dose IL-2 versus placebo for severe alopecia areata completed in 44 patients
Phase 3 trial tests low-dose IL-2 for severe alopecia areata, results pending
A Phase 3, prospective, randomized, double-blind, multicenter trial compared low-dose IL-2 to placebo in 44 patients with severe alopecia ar…
A major late-stage trial testing low-dose IL-2 for severe alopecia areata has finished, but results on hair regrowth are not yet available.
Acthar studied in FSGS patients undergoing renal transplantation to measure recurrence rate
Can a medication help prevent kidney disease from returning after transplant?
A prospective phase 3 study enrolled 15 renal transplant recipients with primary FSGS to evaluate Acthar. The primary endpoint was the rate …
A new kidney transplant study found that Acthar medication may lower the risk of FSGS returning to the new organ, offering hope to patients …
Phase 3 trial of milvexian for ACS prevention completes enrollment
Can a new drug help prevent heart attacks and strokes after a serious heart event?
The LIBERATE trial, a Phase 3 study, has completed enrollment of 14,194 participants with a recent acute coronary syndrome to evaluate if mi…
A new drug called milvexian is being tested to see if it lowers the risk of death, heart attack, or stroke after a serious heart event.
TRACK trial to assess low-dose rivaroxaban for MACE in advanced CKD/dialysis patients
Can a low-dose blood thinner protect people with advanced kidney disease from heart attacks and strokes?
The TRACK trial is a global, quadruple-blind, placebo-controlled phase 3 study evaluating low-dose rivaroxaban (2.5 mg) for reducing major a…
A new global study tested whether a low-dose blood thinner safely protects people with advanced kidney disease from heart attacks and stroke…
Canakinumab shows efficacy in Japanese AOSD patients in Phase 3 open-label study
Could a monthly injection help control the painful flares of Adult-Onset Still's Disease?
A Phase 3, open-label, single-arm study evaluated canakinumab in 14 Japanese patients with Adult-Onset Still's Disease. The primary outcome …
A monthly injection helped Japanese patients with Adult-Onset Still's Disease achieve meaningful symptom relief, supporting approval for thi…
Phase III trial of AK111 for active ankylosing spondylitis completed with 510 patients
Can a new drug help people with painful spinal arthritis move more freely?
A Phase III, randomized, double-blind, placebo-controlled, multicenter study evaluated AK111 in 510 patients with active ankylosing spondyli…
A new drug called AK111 aims to help people with painful spinal arthritis move more freely by improving symptoms like pain and stiffness.
Phase 1/2/3 trial of BNT162b2, BNT162b1, and BNT162b2SA COVID-19 vaccines in 46,969 healthy individuals
How did the original COVID-19 vaccine hold up? A massive study tested its safety and effectiveness in nearly 47,000 people.
This Phase 1/2/3, randomized, placebo-controlled, observer-blind study evaluated the safety, tolerability, immunogenicity, and efficacy of t…
A massive study tested the safety and effectiveness of the original COVID-19 vaccine in nearly 47,000 healthy people across different ages.
Guselkumab Shows Promise in Crohn's Disease: Phase 3 Study Results
Can a new treatment help people with Crohn's disease feel better and stay better?
The Phase 2/3 study evaluates guselkumab's efficacy and safety in Crohn's disease. Primary outcomes include changes in CDAI and clinical rem…
A new Crohn's treatment study with 1,409 participants aims to help people feel better and stay better for up to 48 weeks.
Phase 3 Study Evaluates Barzolvolimab for Chronic Spontaneous Urticaria
Can a new treatment finally help those suffering from chronic hives?
A Phase 3 trial assesses barzolvolimab's efficacy and safety in CSU patients unresponsive to antihistamines.
Adults with chronic hives who don't get relief from standard antihistamines may find new hope in a new treatment called barzolvolimab being …
Triapine Added to Cisplatin and Radiation for Cervical/Vaginal Cancer: Phase III Results
Could a new drug boost survival for women with advanced cervical and vaginal cancers?
Phase III trial evaluates triapine with cisplatin and radiation vs. standard treatment for advanced cervical and vaginal cancers.
A new drug called triapine may help women with advanced cervical and vaginal cancers live longer when added to standard radiation and chemot…
PALaDIN Study: High vs. Low Dose Iron in Peritoneal Dialysis Patients
Can high-dose iron improve health for people on peritoneal dialysis?
The PALaDIN study, a phase 3 trial, is recruiting to compare high-dose and low-dose iron treatments in peritoneal dialysis patients with ana…
People on peritoneal dialysis in the UK may see better health and fewer blood transfusions if they receive high-dose iron instead of low-dos…
Phase 3 Study of Lutetium (177Lu) Vipivotide Tetraxetan in OMPC Patients
Can a new treatment delay prostate cancer from spreading further?
Phase 3 trial evaluates lutetium (177Lu) vipivotide tetraxetan for oligometastatic prostate cancer. Primary outcome: Metastasis Free Surviva…
A new prostate cancer treatment aims to delay cancer spread and spare men from intensive hormone therapy while preserving their quality of l…
Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in Children
Could a New Vaccine Protect Children from Chikungunya Virus?
A Phase 3 trial is assessing the safety and immunogenicity of the CHIKV VLP vaccine in children aged 1 to <12 years. Primary endpoints inclu…
A new vaccine is being tested to protect children aged 1 to under 12 from painful chikungunya fever and joint pain while researchers track s…
Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary Outcome
Could a New Treatment Offer Hope for Patients with Lupus?
In a Phase 3 trial with 367 SLE patients, subcutaneous anifrolumab was tested against placebo. The primary endpoint is the BICLA response, b…
A new subcutaneous treatment is being tested to help adults with moderate to severe lupus who aren't responding well to standard care.
Phase 3 Trial of Cenerimod for Lupus Nephritis: Efficacy and Safety Evaluation
Could a New Drug Help Improve Kidney Function in Lupus Patients?
A Phase 3 trial is assessing cenerimod's efficacy and safety in treating active lupus nephritis. The primary endpoint is complete renal resp…
A new trial tests whether adding cenerimod to regular treatment can improve kidney function in adults with active lupus nephritis over 76 we…
Raloxifene SNP Study: Investigating ER and UGT Gene Impact on Breast Cancer Outcomes
Can a Common Breast Cancer Drug Work Better for Some Patients?
This Phase 2/3 trial examines the relationship between ER and UGT SNPs and Raloxifene's efficacy and side effects in 600 BC-LCIS patients. R…
A study is testing if genetic markers can predict which breast cancer patients respond best to Raloxifene, potentially tailoring treatment f…
MRI-RSI changes during neoadjuvant ADT and radiotherapy in men with high-risk localized prostate cancer
Early MRI scans shrink after treatment to help spot prostate cancer recurrence sooner
This prospective phase II trial protocol reports early results from 97 men with unfavorable-intermediate-risk or high-risk localized prostat…
New MRI scans taken before and during treatment for prostate cancer show clear shrinkage that could help doctors target the tumor more accur…
Eltrombopag plus immunosuppression for severe aplastic anemia shows clonal evolution patterns
Treatment for severe anemia reveals two paths to cancer risk
This phase 2 observational study followed 204 patients with severe aplastic anemia treated with immunosuppression plus eltrombopag for a med…
New research tracks cancer risks in severe anemia patients treated with standard therapy over five years
Burosumab improves phosphate levels in 12 children and adults with fibrous dysplasia over 48 weeks.
Burosumab Restores Phosphate Balance in Rare Bone Disease
This Phase 2 trial enrolled 12 participants (7 children, 5 adults) with fibrous dysplasia to assess burosumab. At 48 weeks, 100% achieved ph…
A drug already used for rare phosphate disorders may finally offer real relief for people with fibrous dysplasia, a painful bone condition t…
Abexinostat showed a 69.5% objective response rate in relapsed follicular lymphoma patients.
New Drug Shrinks Stubborn Lymphoma Tumors After Other Treatments Fail
This single-arm, multi-center phase 2 study evaluated abexinostat in 90 patients with relapsed or refractory follicular lymphoma who had rec…
A new treatment is helping some patients with stubborn lymphoma shrink tumors and stay in control for over a year, even after other therapie…
Phase 2 trial of pembrolizumab and DNA vaccines in metastatic prostate cancer shows no significant difference
Prostate Cancer Vaccine Strategy Shows Tumor Responses, But One Arm Adds Risk
This early Phase 2 trial evaluated pembrolizumab combined with pTVG-HP or pTVG-AR DNA vaccines in 60 patients with metastatic castration-res…
A two-vaccine strategy did not improve survival over a single vaccine in advanced prostate cancer, yet both approaches shrank tumors in some…
EMS Bundle for Pediatric Life-Threatening Asthma Evaluated in PECARN Pilot
Early Meds Could Cut Hospital Stays for Wheezing Kids
This Phase 2 pilot trial in the Pediatric Emergency Care Applied Research Network assessed an EMS treatment bundle and checklist for childre…
Kids with severe asthma might avoid hospital stays if they get breathing meds right after the 911 call.
Spanish RSBQ Validation in 51 Latin American Rett Syndrome Caregivers
New Spanish Tool for Rett Syndrome Improves Care for Thousands
This observational linguistic validation study assessed a Spanish translation of the Rett Syndrome Behaviour Questionnaire among 51 Spanish-…
A Spanish-language behavior checklist for Rett Syndrome now matches the English version, helping Spanish-speaking families get more accurate…
Eltrombopag monotherapy assessed in moderate aplastic anemia and unilineage bone marrow failure disorders.
Oral Drug May Reduce Need for Frequent Blood Transfusions
This Phase 2 trial evaluated eltrombopag by mouth once a day in 34 people at least 2 years of age with moderate aplastic anemia or unilineag…
A new oral medication offers hope for patients who rely on regular blood transfusions.
Camrelizumab plus nab-paclitaxel showed modest activity in previously treated advanced urothelial carcinoma patients.
New Treatment Extends Life for Bladder Cancer Patients
This multicenter Phase II study evaluated camrelizumab plus nab-paclitaxel in 60 patients with advanced urothelial carcinoma who progressed …
For years, Mark, 64, thought he’d beaten cancer.
Vosoritide daily injections in prepubertal hypochondroplasia patients over 12 months
Vosoritide Changes Growth Hormone Signals
This phase 2, single-arm, unblinded trial evaluated daily vosoritide 15 μg/kg in prepubertal patients aged 3 to 11 years with hypochondropla…
This new research shows how a specific growth medicine works inside the body to help short children grow taller.
Envafolimab plus lenvatinib and paclitaxel shows activity in advanced gastric cancer after first-line progression.
New Drug Combo Gives Hope for Late-Stage Stomach Cancer
This phase II, single-center, open-label trial evaluated envafolimab combined with lenvatinib and albumin-bound paclitaxel in 30 patients wi…
Imagine a patient who has already tried every standard treatment available.
Neoadjuvant atezolizumab shows spatial biomarker changes in operable urothelial carcinoma patients.
How a Bladder Cancer Drug Remodels the Tumor Neighborhood
This single-arm, phase II trial evaluated neoadjuvant atezolizumab in patients with operable urothelial carcinoma. Results indicated that ce…
A bladder cancer drug physically breaks down the walls blocking immune cells in tumors, helping doctors predict which patients will respond …
Savolitinib and durvalumab combination yields response rates of 34% to 53% in papillary renal cancer patients.
New Hope for a Tough Kidney Cancer Type
This single-arm phase II study evaluated savolitinib and durvalumab in 41 treatment-naïve or pretreated patients with papillary renal cancer…
A new drug pair breaks the shield blocking treatment for a rare kidney cancer type, offering patients a chance at longer survival after stan…
Extensive intraoperative peritoneal lavage after gastrectomy for gastric cancer with peritoneal cytology positivity.
Can washing the belly during surgery help prevent stomach cancer from coming back?
This single-arm exploratory phase 2 trial in 13 patients with gastric cancer and positive peritoneal cytology evaluated extensive intraopera…
A thorough belly wash during stomach cancer surgery kept patients free from recurrence for 14.5 months if their fluid tests showed no cancer…
MRIRA annotation scheme shows high agreement for medication safety incident reports in NHS
Can computers reliably read your hospital safety reports about medication errors?
A methodological study developed and evaluated the Medication-Related Incident Report Annotation (MRIRA) scheme using 55 and 30 healthcare i…
Computers can read hospital safety reports about medication errors with 85% to 91% accuracy, though they struggle with complex details.
Phase 1b trial of intravenous B001 shows favorable safety in aquaporin-4-positive NMOSD patients.
A New MS-Like Disease Drug Passes Its First Human Safety Test
This Phase 1b randomized, double-blind, placebo-controlled trial evaluated intravenous B001 in 22 patients with aquaporin-4 immunoglobulin G…
A new drug for a rare nerve disease that can cause blindness and paralysis passed its first human safety test with no severe side effects se…
Phase Ia trial of RH5.1 protein with Matrix-M adjuvant in malaria-naive UK adults showed safety and similar immunogenicity across two booster regimens.
A Malaria Vaccine Candidate Holds Strong — Even With a Smaller Booster Dose
This Phase Ia clinical trial evaluated the safety and immunogenicity of RH5.1 soluble protein with Matrix-M adjuvant in malaria-naive UK adu…
A malaria vaccine candidate produced strong immune responses even when the final booster dose was cut in half, potentially helping extend va…
Talquetamab and teclistamab combination shows 79% response in relapsed multiple myeloma with extramedullary disease.
Study looks at two antibody drugs for high-risk multiple myeloma
This phase 2 single-arm study evaluated a talquetamab and teclistamab combination in a high-risk population with relapsed/refractory multipl…
A new drug combo for high-risk multiple myeloma helped 79% of patients respond, but 31% faced serious infections and five treatment-related …
Tucidinostat plus capecitabine shows 25.8% response in advanced HR-positive HER2-negative breast cancer
New Drug Combo Helps Breast Cancer After CDK4/6 Failure
This phase 2 trial evaluated tucidinostat plus metronomic capecitabine with endocrine therapy in 66 patients with HR-positive HER2-negative …
A new drug mix shrinks tumors in advanced breast cancer patients whose disease grew after standard treatments failed.
Phase 2 trial tests single-dose IV iron isomaltoside in severe aortic stenosis with iron deficiency
Early study suggests iron treatment may help heart function in severe aortic stenosis patients.
This Phase 2, double-blind, randomized, placebo-controlled trial tested a single intravenous dose of iron isomaltoside versus placebo in pat…
Treating iron deficiency may improve exercise capacity and reduce fatigue in people with severe aortic stenosis, according to early trial re…
Pilot study of fluoxetine and calcium in musculoskeletal trauma victims showed no measurable benefit.
A Common Antidepressant May Ease Recovery After Serious Injuries
This pragmatic pilot study evaluated fluoxetine and calcium in 68 victims of musculoskeletal trauma. Follow-up occurred at 41.6 months, but …
A common low-dose antidepressant may help adults recover emotionally after serious bone and joint injuries, addressing the hidden mental tol…
Becotatug vedotin shows 20.9% objective response in recurrent head and neck squamous cell carcinoma after prior therapy
For patients with advanced head and neck cancer, a new drug showed a 21% response rate in early testing.
This multicenter, Phase IIa trial evaluated intravenous becotatug vedotin in 67 patients with recurrent or metastatic squamous cell carcinom…
A new drug shrank tumors in 21% of patients with advanced head and neck cancer who had run out of standard treatment options.
Adapted-dose FOLFIRINOX assessed for safety and early efficacy in elderly patients with metastatic pancreatic cancer.
New Drug Combo Helps Older Pancreatic Cancer Patients Live Longer
This Phase II multicentric study evaluated adapted-dose FOLFIRINOX in 72 elderly patients (aged 70 years or older) with metastatic pancreati…
A new drug mix helps older pancreatic cancer patients live longer while keeping them active, provided doctors check specific genes first to …
Neoadjuvant nivolumab alone or with ipilimumab in cisplatin-ineligible muscle-invasive bladder cancer
Hope for Bladder Cancer When Chemo Isn't an Option
This Phase II trial evaluated neoadjuvant nivolumab alone or with ipilimumab in 30 cisplatin-ineligible patients with muscle-invasive bladde…
Patients with advanced bladder cancer who can't take standard chemo may now qualify for surgery after a new immunotherapy treatment.
SABR shows 46% 5-year overall survival in unfit NSCLC patients in phase 2 trial
Precision Radiation Offers a Real Option for Lung Cancer Patients Who Can't Do Chemo
A non-randomized phase 2 trial of 50 patients with unresectable locally advanced NSCLC unfit for concurrent chemoradiation found 5-year over…
Nearly half of patients treated with precision radiation were still alive at five years, offering hope for lung cancer patients too frail fo…
Regorafenib plus nivolumab in second-line hepatocellular carcinoma showed safety and survival signals in a Phase IIa trial.
Some Liver Cancer Patients Are Surviving Far Longer on a New Drug Combination
This Phase IIa trial evaluated regorafenib plus nivolumab as an add-on therapy in patients with hepatocellular carcinoma who had progressed …
A combination of regorafenib and nivolumab showed unexpectedly long survival in people with advanced liver cancer who had already exhausted …
![In a phase 2 trial, [Ga]Ga-SSO120 PET/CT detected malignancies in 18 of 19 patients with small cell or large cell neuroendocrine lung cancer.](/assets/images/defaults/pulmonology-5.jpg)
In a phase 2 trial, [Ga]Ga-SSO120 PET/CT detected malignancies in 18 of 19 patients with small cell or large cell neuroendocrine lung cancer.
A New Scan That Lights Up Hidden Lung Cancer Spread
This prospective, phase 2, cross-sectional imaging trial evaluated [Ga]Ga-SSO120 PET/CT versus CT in 19 patients with small cell lung cancer…
A new kind of PET scan found hidden tumors in patients with aggressive lung cancer, including bone and brain spread that standard imaging mi…
Stereotactic body radiotherapy for painful spinal metastases showed high pain response rates in a single-arm phase II study.
Second Radiation Stops Spinal Pain Fast
This single-centre, single-arm phase II study evaluated re-irradiation stereotactic body radiotherapy (SBRT) in 34 patients with painful spi…
A second round of precise radiation safely stops severe spinal pain in most patients, offering new hope for those who previously had no opti…
Ibrutinib monotherapy showed durable progression-free survival in patients with TP53 aberrations or advanced age.
Ten Years on One Pill: What Long-Term Ibrutinib Revealed
This investigator-sponsored phase 2 study evaluated single-agent ibrutinib in 84 patients with chronic lymphocytic leukemia (CLL) harboring …
A decade of follow-up shows a daily pill can give high-risk leukemia patients years of control, but staying on it is not easy.
Low OT-NLR predicts superior survival in recurrent/metastatic HNSCC treated with cetuximab plus nivolumab
A Simple Blood Ratio May Predict Cancer Drug Success
This Phase II clinical trial evaluated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) receiving combine…
A low white blood cell ratio found in blood tests predicts better survival and treatment response for advanced head and neck cancer patients…
Talazoparib monotherapy in neoadjuvant triple-negative breast cancer reveals BRN2-driven resistance mechanisms.
Why Some BRCA Breast Cancers Shrug Off Talazoparib Before Surgery
This Phase II neoadjuvant trial evaluated talazoparib in patients with germline mutant breast tumors. Mechanistic analysis showed that BRN2 …
Some BRCA breast cancers shrink under talazoparib, but others find hidden escape routes that let them ignore the drug before surgery.
Itacitinib plus standard therapy in acute leukemia or myelofibrosis patients undergoing reduced-intensity conditioning donor stem cell transplantation
Early trial explores itacitinib for stem cell transplant patients with blood disorders
This Phase IIa trial evaluated itacitinib combined with tacrolimus and sirolimus in patients with acute leukemia, myelodysplastic syndrome, …
A new trial adds itacitinib to standard care for stem cell transplant patients with blood disorders to help prevent graft-versus-host diseas…
Becotatug vedotin shows antitumor activity in pretreated recurrent or metastatic nasopharyngeal carcinoma
A New Drug Shows Promise for Tough-to-Treat Nasopharyngeal Cancer
A phase IIa single-arm trial of 61 patients with platinum-refractory recurrent or metastatic nasopharyngeal carcinoma found an objective res…
For patients with a hard-to-treat head and neck cancer who have few treatments left, a new experimental therapy is showing encouraging resul…
First-line osimertinib shows high response rates in EGFR-mutated NSCLC with active brain metastases.
Untreated Brain Metastases Respond Well to Osimertinib
This single-arm phase II trial evaluated first-line osimertinib in 100 patients with EGFR-mutated non-small cell lung cancer, including thos…
Osimertinib, a lung cancer drug, effectively treats untreated brain metastases, with an 81.8% response rate for measurable brain spots in a …
Phase 2 trial of JNJ-73763989-based regimen shows no HBsAg seroclearance at primary endpoint in HBeAg-positive CHB
New combo lowers hepatitis B virus levels
A phase 2 trial in 54 treatment-naïve, HBeAg-positive chronic hepatitis B patients tested a regimen of JNJ-73763989 ± bersacapavir with nucl…
A new drug combination successfully lowered virus levels in many patients, though clearing the virus completely happened in only about one o…
SBRT plus PD-1 inhibitor and lenvatinib improved PFS in oligoprogressive HCC patients.
Radiation Plus Immune Drugs Stops Liver Cancer Growth
This prospective Phase 2 study evaluated stereotactic body radiation therapy (SBRT) combined with continued first-line PD-1 inhibitor-based …
Combining targeted radiation with ongoing immune therapy can restart cancer control in patients whose disease was slowly spreading again.
Trifluridine/tipiracil plus irinotecan and bevacizumab in metastatic colorectal cancer resistant to prior chemotherapy
A New Second-Line Combo Shows Promise for Advanced Colon Cancer
This multicenter, single-arm, phase II trial evaluated biweekly trifluridine/tipiracil, irinotecan, and bevacizumab in 60 patients with meta…
For patients whose advanced colon cancer has stopped responding to initial chemo, a new drug combination is showing it can effectively fight…
BCMA CAR-T therapy achieves 100% MRD negativity in transplant-ineligible multiple myeloma patients.
A One-Time Treatment Erases Early-Stage Blood Cancer in Older Adults
This Phase II, open-label, single-arm trial evaluated BCMA CAR-T infusion in 36 patients with newly diagnosed multiple myeloma ineligible fo…
A new approach using a patient’s own re-engineered immune cells is showing unprecedented success in wiping out a common blood cancer from th…
AN+AD combination therapy yields high response rates in nonbulky classical Hodgkin lymphoma patients.
A New Treatment Path for Hodgkin Lymphoma Shows Stunning Success
This Phase 2 study evaluated AN+AD (brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine) in 154 patients with nonbulky classical Ho…
A promising new treatment approach for early-stage Hodgkin lymphoma is delivering remarkable results with less intensive chemotherapy.
Olaparib plus durvalumab showed activity in mCRPC patients previously treated with abiraterone or enzalutamide.
Two Cancer Drugs Teamed Up — Who Actually Benefits Most?
This single-arm, open-label phase 2 trial evaluated olaparib plus durvalumab in 60 men with metastatic castration-resistant prostate cancer …
A new prostate cancer drug combo helped men with specific DNA repair gene variants live more than twice as long without their cancer progres…
Liquid biopsy shows high sequencing success in high-risk localized prostate cancer feasibility study
Blood Tests Replace Biopsies for Prostate Cancer
A phase 2 neoadjuvant trial in 22 patients with high-risk localized prostate cancer found liquid-based genomic profiling achieved 100% seque…
A simple blood draw now replaces painful prostate biopsies, capturing the same genetic details doctors need to pick the best treatment.
Encorafenib plus binimetinib maintains quality of life in BRAF V600E-mutated thyroid cancer
Can new drugs help advanced thyroid cancer patients keep their daily life stable?
An uncontrolled phase 2 trial of 22 patients with BRAF V600E-mutated thyroid cancer found encorafenib plus binimetinib was associated with g…
A new drug combination helped advanced thyroid cancer patients maintain daily life stability without worsening their quality of life during …
Simulation study suggests BF-BOLD reduces overdose rates and enhances safety in Phase I trials compared to conventional designs.
Can a smarter trial design make early cancer drug tests safer and more sustainable?
This Phase I simulation study compared the Backfill Bayesian Ordered Lattice Design (BF-BOLD) against conventional Phase I trial designs. Th…
A smarter trial design reduces overdose rates and improves safety while preserving drug effectiveness during early cancer tests.
Ponatinib in CP-CML resistant to prior TKI or T315I mutation showed molecular response at Month 12
Ponatinib doses show early signs in resistant chronic myeloid leukemia patients
This Phase 2 study evaluated ponatinib in 283 participants with chronic-phase chronic myeloid leukemia (CP-CML) resistant to prior tyrosine-…
Ponatinib at three daily doses showed early signs of helping resistant chronic myeloid leukemia patients reach a key molecular response goal…
Phase 2 trial compares Inotuzumab Ozogamicin plus R-CVP for DLBCL patients unfit for anthracycline
Can a new drug combination help lymphoma patients who can't take standard chemo?
A Phase 2 interventional trial enrolled 129 patients with diffuse large B-cell lymphoma (DLBCL) who were unsuitable for anthracycline-contai…
A new drug combo aims to treat aggressive lymphoma in older patients who can't take standard chemo due to heart risks.
In children with Ph+ ALL, TKI-based therapy reduced HSCT use while maintaining comparable outcomes versus Ph+ALL04.
Reduced transplant use showed similar outcomes in children with Philadelphia chromosome-positive leukemia
This single-arm Phase 2 trial evaluated chemotherapy with tyrosine kinase inhibitors (TKIs) guided by minimal residual disease in 41 eligibl…
Children with a specific leukemia type achieved similar survival rates without stem cell transplants, offering a less intensive treatment op…
Chinese rehabilitation students show low knowledge of physical activity guidelines; learning linked to practice
Do future physical therapists learn how to prescribe exercise? Many don't.
A mixed-methods study of 105 Chinese rehabilitation students and 10 therapists found 66.7% of students reported not being taught WHO physica…
Two-thirds of Chinese physical therapy students were never taught how much exercise is healthy, leaving many future therapists unprepared to…
Phase II trial shows high remission and survival with frontline ATRA-ATO for newly diagnosed APL
Can a chemotherapy-free treatment beat a rare, aggressive leukemia?
A prospective multicenter phase II trial in 81 newly diagnosed APL patients in Japan found that frontline ATRA-ATO therapy achieved a 95.1% …
A chemotherapy-free treatment for acute promyelocytic leukemia achieved 95% remission and 95% survival three years later in a Japanese trial…
Centralized hair loss measurement showed better agreement and 50% lower error margins than local rating in mild-to-moderate Alopecia Areata.
Centralized hair loss scoring showed better consistency than local ratings in mild Alopecia Areata trials
This Phase 2 clinical trial compared centralized measurement of hair loss via standardized photographic images against local SALT score rati…
Centralized hair loss scoring cut measurement errors by half compared to local ratings in mild Alopecia Areata trials, boosting trial succes…
Regional motif diversity score in cfDNA predicts pembrolizumab response in head and neck cancer
Can a DNA pattern predict who will heal from head and neck cancer immunotherapy?
A phase II trial in 68 patients with locally advanced, resectable HNSCC found that a regional motif diversity score (rMDS) in cell-free DNA …
A new DNA pattern in blood can reliably predict which head and neck cancer patients will respond to immunotherapy and live longer without th…
Phase II studies evaluate tislelizumab plus sitravatinib or anlotinib maintenance in extensive-stage small-cell lung cancer.
Can adding two drugs after chemo help some lung cancer patients survive longer?
These prospective phase II single-arm studies assessed tislelizumab combined with sitravatinib or anlotinib as maintenance therapy in previo…
Adding tislelizumab plus sitravatinib or anlotinib after chemo kept some small-cell lung cancer patients cancer-free for 6.4 to 7.8 months.
Hypofractionated stereotactic radiation therapy showed high local control in breast cancer brain metastases.
FSRT shows promising results for brain metastases in breast cancer patients
This prospective single-arm phase 2 trial evaluated fractionated stereotactic radiation therapy (FSRT) in 173 patients with breast cancer an…
Fractionated stereotactic radiation therapy kept brain cancer controlled in 88.6% of breast cancer patients after one year with no severe si…
In Silico Modeling Predicts Fezolinetant Hepatotoxicity Risk in MAFLD Population
Could a menopause drug harm the liver? A computer model offers clues.
Quantitative systems toxicology modeling simulated fezolinetant hepatotoxicity in virtual populations. The model predicted no ALT elevations…
A computer model predicts a menopause drug might cause rare liver injury in people with fatty liver disease, but higher doses could be safer…
BACE plus tislelizumab shows activity in advanced NSCLC patients ineligible for standard care
Combination treatment shows promise for advanced lung cancer patients ineligible for standard care
A Phase II, single-arm trial in 30 patients with Stage IIIA-IIIC NSCLC who refused or were ineligible for standard treatment evaluated bronc…
A new combo treatment for advanced lung cancer patients ineligible for standard care helped 60% shrink tumors and extended survival to 15 mo…
Durvalumab plus chemotherapy shows 35% response in phase II trial for metastatic pulmonary sarcomatoid carcinoma
Small study tests drug combination for rare, aggressive lung cancer
A phase II single-arm trial in 20 patients with recurrent/metastatic pulmonary sarcomatoid carcinoma evaluated durvalumab plus doxorubicin/i…
A rare lung cancer drug combo shrank tumors in 35% of patients, offering hope for those with this aggressive disease despite common side eff…
Phase 2a trial of dazodalibep plus belatacept shows 25% acute rejection rate in kidney transplant patients
Early study tests two-drug combination to prevent kidney transplant rejection
A phase 2a, open-label, single-arm trial in 23 adults undergoing first kidney transplants evaluated dazodalibep plus belatacept as sole main…
A new two-drug kidney treatment was safe but failed to prevent rejection in most patients during this early study.
Phase 2 trial of muscadine grape extract added to ADT for recurrent prostate cancer fatigue
Muscadine grape extract studied for fatigue in men with recurrent prostate cancer
A Phase 2 randomized controlled trial enrolled 106 men with recurrent prostate cancer on androgen deprivation therapy to test muscadine grap…
Men with recurrent prostate cancer taking hormone therapy may feel less extreme fatigue when adding a natural muscadine grape extract supple…
Phase 2 trial assesses JYNNEOS vaccine in adolescents for monkeypox prevention
Is the monkeypox vaccine safe and effective for teenagers?
A Phase 2 open-label, non-placebo controlled trial evaluated the standard subcutaneous JYNNEOS regimen in 315 vaccinia-naïve adolescents (12…
A new study is looking at whether the standard monkeypox vaccine works for adolescents. Researchers compared immune responses and side effec…
Single-fraction stereotactic partial breast irradiation shows promising early control in early-stage breast cancer
Can a single radiation dose protect women after breast cancer surgery?
A prospective single-institution phase 2 trial of 148 patients with early-stage breast cancer after breast-conserving surgery found single-f…
A single radiation dose for breast cancer recovery showed low recurrence and mild side effects in early results from a new treatment approac…
Qualitative study finds knowledge gaps and insurance concerns about prostate cancer genetic testing
What stops men from getting genetic testing for prostate cancer?
A qualitative and survey study of 20 men with prostate cancer, plus patients, carers, and healthcare providers, found generally low knowledg…
Fear of insurance discrimination and low knowledge about genetic testing are stopping many men from getting prostate cancer tests that could…
Neoadjuvant sacituzumab govitecan plus pembrolizumab shows 39% clinical complete response in MIBC
Drug combination shows promise for bladder cancer patients who cannot take standard chemotherapy
A single-arm phase 2 study of 49 patients with muscle-invasive bladder cancer ineligible for cisplatin found a clinical complete response ra…
A new drug combination helped 39% of bladder cancer patients who couldn't take standard chemotherapy achieve a complete response before surg…
Phase 2 trial proposes 129XeMRI and RNA sequencing to study airway remodeling in obese asthma
Can a new type of lung scan reveal why asthma hits obese people harder?
A Phase 2 clinical trial proposal aims to use hyperpolarized 129XeMRI and single-cell RNA sequencing to investigate mechanisms of regional a…
A new lung scan maps hidden scarring in obese asthma patients, helping explain why these breathing problems are harder to treat than in othe…
Phase 2 trial protocol tests oral hydrocortisone for PTSD prevention after trauma
Study tests single hydrocortisone pill after trauma to prevent PTSD symptoms
A phase 2 randomized controlled trial protocol describes a study of 201 trauma survivors in emergency departments. Participants receive a si…
A single hydrocortisone pill taken within six hours of trauma might help the brain process memories differently to prevent PTSD symptoms in …
Radiomics models predict progression in lung oligometastases after SABR in phase II trial
Radiomics models show promise for predicting outcomes after lung metastasis radiation
A single-arm phase II trial of 126 patients with lung oligometastases developed radiomics models to predict progression-free survival and ea…
Computer analysis of medical scans can better predict when lung cancer will spread after radiation treatment than standard clinical informat…
Phase 2 trial of ketamine for tinnitus in 42 adults did not report main results
Can a single ketamine dose quiet the brain's noise in people with tinnitus?
A phase 2 clinical trial investigated ketamine hydrochloride versus placebo in 42 adults with tinnitus. The primary outcome was GABA and Glx…
A single ketamine dose may quiet brain noise in tinnitus by blocking glutamate receptors and boosting calming GABA chemicals, offering hope …
Phase 2 trial of Paxlovid for Long COVID cognitive, autonomic, and exercise symptoms completed.
Can Paxlovid help people with Long COVID? A major trial is underway.
A prospective, multi-center, double-blind, randomized, controlled Phase 2 trial enrolled 964 individuals with PASC to evaluate Paxlovid. The…
A major trial is testing whether Paxlovid can ease Long COVID symptoms like brain fog and severe fatigue in nearly 1,000 people.
Cryoablation shows 3.64% 5-year recurrence in selected early-stage breast cancer patients
Cryoablation shows low recurrence rate in early-stage breast cancer after six years
A prospective phase 2 multicenter study of 83 women aged ≥50 with stage I, HR+, HER2-, node-negative invasive ductal carcinoma found a 5-yea…
Cryoablation kept early-stage breast cancer from returning in 97.6% of women over six years, with no serious side effects reported in this s…
ENGAGE program shows feasibility and preliminary signal for participation after chronic stroke in pilot trial
Can a peer-led program help stroke survivors reconnect with their communities?
A phase 2a single-arm pilot trial of 30 community-dwelling stroke survivors assessed a 6-week ENGAGE intervention co-facilitated by peer men…
A new stroke support program helped 30 survivors reconnect with their communities, showing high satisfaction and safe participation in socia…
Phase 2 trial compares lidocaine/estradiol cream, nortriptyline, and combination for vestibulodynia subtypes
Can a cream or pill help women with chronic pelvic pain?
A 52-month, phase 2, randomized, double-blinded, placebo-controlled trial in 209 women with distinct vestibulodynia subtypes compared 5% lid…
Women with chronic pelvic pain may finally find relief as a new trial compares creams, pills, and combined treatments to personalize care fo…
Phase II trial opens for Viscum album extract adjuvant therapy in relapsed osteosarcoma
Early study explores mistletoe extract as additional treatment for relapsed bone cancer in young people
A Phase II trial is now open to evaluate adjuvant Viscum album extract (Iscador® P) in children and AYAs with relapsed, resectable osteosarc…
A pilot study found that adding mistletoe extract after surgery helped 55% of young people with relapsed bone cancer stay alive without dise…
Envafolimab plus lenvatinib and capecitabine shows activity in resected biliary tract cancer
Combination therapy shows promise for preventing biliary tract cancer recurrence after surgery
A single-arm phase II trial in 28 patients with resected biliary tract cancer at high risk of recurrence found median disease-free survival …
A new three-drug combination helped 68% of high-risk biliary tract cancer patients stay cancer-free for a year after surgery, with 91% still…
Larger baseline tumor burden linked to shorter OS in rare cancers treated with nivolumab plus ipilimumab
Does tumor size predict how well immunotherapy works for rare cancers?
A secondary analysis of a phase 2 basket trial in 722 patients with rare/ultrarare malignancies found that larger baseline tumor burden was …
For rare cancers treated with immunotherapy, larger tumors at the start were linked to shorter overall survival, but not to how long patient…
Phase 2 trial links early monocyte elevation to response in gastric cancer immunotherapy
Small study finds immune cell changes linked to better response in gastric cancer treatment
A phase 2 trial in 24 patients with metastatic gastric cancer receiving first-line pembrolizumab plus XELOX found that early elevation of ci…
Patients with metastatic gastric cancer who saw early immune cell changes in their blood were more likely to survive longer while receiving …
CD8 PET imaging shows modest correlation with biopsy CD8 counts in solid tumor patients on immunotherapy
New imaging method shows modest link to immune cell counts in solid tumors
A Phase II prospective multicenter study of 49 patients with solid tumors receiving immune checkpoint blockade found a modest correlation (c…
A new PET scan shows a modest link to immune cell counts inside solid tumors, with stronger results in kidney cancer patients.
Phase 2 trial of oral ifetroban in DMD cardiomyopathy reports no safety results yet
Can a new pill help protect the hearts of boys with Duchenne muscular dystrophy?
A phase 2 randomized, double-blind, placebo-controlled trial evaluated low- and high-dose oral ifetroban in 46 males with DMD-associated car…
A new pill called ifetroban is being tested to safely treat heart weakness in boys with Duchenne muscular dystrophy, addressing a leading ca…
Phase II study of 177Lu-PSMA-617 in mCRPC shows 50% PSA response and median OS of 18.8 months
Can a targeted radiation treatment help men with advanced prostate cancer?
A prospective, single-arm phase II study of 48 PSMA-avid mCRPC patients treated with 177Lu-PSMA-617 found a 50% PSA response rate and median…
A targeted radiation therapy helped half of men with advanced prostate cancer lower their cancer markers and kept nearly 88% alive after one…
Phase 2 trial of high-dose thoracic reirradiation shows 30-month median OS for recurrent lung cancer
Can high-dose radiation help when lung cancer returns near where it was treated before?
A phase 2 single-arm trial of 60 patients with recurrent lung cancer in the thorax found that high-dose reirradiation (≥45 Gy EQD) achieved …
When lung cancer returns near a previous radiation site, a precise high-dose treatment helped patients survive a median of 30 months with no…
Phase 2 trial tests pre-hospital glucocorticoid pulse in STEMI patients undergoing primary PCI
Phase 2 trial tests steroid pulse for heart attack patients before hospital arrival
A phase 2 randomized controlled trial enrolled 530 STEMI patients treated with primary PCI to test single-dose glucocorticoid pulse therapy …
A new trial tested giving a single steroid dose in ambulances before heart attack patients reach the hospital to reduce permanent heart dama…
Phase II trial of rucaparib maintenance in metastatic endometrial cancer completes follow-up
Can a maintenance drug help keep advanced endometrial cancer at bay?
A phase II randomized controlled trial evaluated rucaparib maintenance versus placebo in 79 patients with metastatic/recurrent endometrial c…
A trial testing rucaparib as maintenance therapy for advanced endometrial cancer has finished, but results on whether it delays cancer growt…
Phase 2 trial of DS-1062a in pretreated advanced NSCLC with genomic alterations posts no results
Phase 2 trial tests DS-1062a drug for advanced lung cancer with specific genetic changes
A Phase 2 interventional trial evaluated DS-1062a (6.0 mg/kg) in 137 participants with advanced/metastatic NSCLC with actionable genomic alt…
A completed Phase 2 trial tested DS-1062a for advanced lung cancer in 137 people who had already received prior chemotherapy and targeted th…
Phase I/II trial tests IMRT with chemotherapy before transplant for relapsed/refractory ALL/AML
Can a new radiation technique make stem cell transplants safer for leukemia?
A phase I/II trial record describes a study of intensity-modulated radiation therapy with etoposide and cyclophosphamide followed by allogen…
Doctors are testing a precise radiation technique to protect healthy organs while preparing patients for life-saving stem cell transplants.
Phase 2 trial explores idelalisib plus ofatumumab in untreated CLL/SLL requiring treatment
Can two drugs together help people with untreated blood cancer?
A phase 2 interventional trial evaluated idelalisib plus ofatumumab in 27 previously untreated CLL/SLL patients requiring therapy. The prima…
For people newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who need treatment, researchers tested a combinat…
Phase 2 trial tests amlitelimab add-on therapy in adults with moderate-to-severe asthma
Phase 2 trial tests new asthma drug amlitelimab in adults with moderate-to-severe asthma
A phase 2 randomized controlled trial enrolled 437 adults with moderate-to-severe asthma globally to evaluate amlitelimab versus placebo. No…
A new asthma drug called amlitelimab is being tested to see if adding it to current treatments can reduce severe asthma attacks in adults wi…
Phase 2 study of lifileucel TIL therapy in 220 patients with metastatic melanoma
Can a patient's own immune cells be turned into a treatment for advanced melanoma?
A prospective, multicenter, phase 2 interventional study evaluated lifileucel (autologous tumor-infiltrating lymphocytes, LN-144) infusion a…
A new treatment uses a patient's own immune cells to fight advanced melanoma, but results from the mid-stage trial are not yet available.
Phase 1/2a trial tests oral idebenone safety in adults with NASH and fibrosis
Can an oral drug help people with fatty liver disease? Early safety study begins.
A randomized, double-blinded, placebo-controlled, single-center phase 1/2a study enrolled 53 adults with NASH and stage 1-3 fibrosis to asse…
A new oral drug for fatty liver disease has finished its early safety study, with results expected soon to show if it helps stop scarring.
Phase 2 trial tests three Vitamin E doses versus placebo in 200 adults with NAFLD
Vitamin E dosing study in 200 adults with fatty liver disease completes trial
A phase 2 randomized controlled trial enrolled 200 adults with NAFLD to compare three doses of Vitamin E (200 IU, 400 IU, 800 IU) with place…
A completed trial on Vitamin E for fatty liver disease has finished, but the results showing if the doses helped or caused harm are not yet …
Capmatinib shows efficacy in Chinese NSCLC patients with MET exon 14 skipping mutations
Could a targeted pill help Chinese patients with a specific lung cancer mutation?
An open-label, multicenter phase II study evaluated capmatinib in 36 Chinese adult patients with advanced NSCLC harboring MET exon 14 skippi…
A targeted pill shrank tumors in Chinese lung cancer patients with a specific MET gene mutation, offering a new treatment option for this ge…
CFZ533 vs Tacrolimus in Kidney Transplant: Phase 2 Study Terminated After Interim Analysis
Did a new drug for kidney transplant patients work better than standard treatment?
A Phase 2 study comparing the anti-CD40 monoclonal antibody CFZ533 to tacrolimus for preventing organ rejection in kidney transplant recipie…
A planned five-year kidney transplant drug trial ended early after an interim look, leaving the key question about the new treatment's perfo…
Letrozole reduces Ki67 in postmenopausal ER+/HER2- breast cancer after 7-30 days pre-surgery
Can a short course of letrozole before surgery help shrink hormone-sensitive breast cancer?
A phase 2 trial of 61 postmenopausal women with ER+/HER2- operable breast cancer evaluated a 7- to 30-day preoperative course of letrozole 2…
Doctors can now get a real-time snapshot of how hormone-sensitive breast cancer responds to letrozole before surgery in postmenopausal women…
Phase II trial of cyclophosphamide, paclitaxel, trastuzumab in stage I-II HER2+ breast cancer completes with 20 patients
Can a shorter, more intense chemo regimen help prevent early-stage HER2-positive breast cancer from returning?
A phase II trial evaluated a dose-dense regimen of cyclophosphamide, paclitaxel, and trastuzumab after surgery in 20 patients with stage I-I…
For women with early-stage HER2-positive breast cancer, a key question is whether a shorter, more intense chemotherapy schedule after surger…
Phase II trial tests induction chemo with carboplatin, paclitaxel, lapatinib before transoral surgery in SCCHN
Can a gentler, three-part treatment plan reduce side effects for head and neck cancer?
A single-arm phase II trial enrolled 40 previously untreated patients with SCCHN amenable to transoral surgery. Treatment involved 6 weeks o…
A three-part treatment plan for head and neck cancer aims to reduce harsh side effects by tailoring care based on surgery results.
Phase 2 pilot study evaluates ticagrelor monotherapy safety after stenting for acute MI
Can a single blood thinner prevent heart attacks after stent placement?
A single-center, single-arm, prospective phase II pilot study of 200 patients assessed the initial safety of ticagrelor monotherapy after co…
A new pilot study tests if one blood thinner alone can safely prevent heart attacks and stent clots after stent placement for heart attack p…
Phase 2a trial of DFV890 and MAS825 for inflammation in CHD/CHIP patients completes with 31 participants
Can two experimental drugs calm the dangerous inflammation linked to heart disease and a blood condition called CHIP?
A Phase 2a, multi-center, randomized, placebo-controlled, blinded study evaluated the efficacy, safety, and tolerability of DFV890 (oral dai…
A new trial tested two experimental drugs to safely turn down the dangerous inflammation driving heart disease in patients with CHIP.
SVRD yields 89.7% ORR, 79.3% EMD resolution in NDMM with EMD in phase 2 trial
Can a new drug combination help people with aggressive multiple myeloma? Early results show promise.
In a phase 2 trial of 29 patients with newly diagnosed multiple myeloma and extramedullary disease (EMD), selinexor combined with VRD (SVRD)…
A new four-drug combination helped nearly 90% of patients with aggressive multiple myeloma shrink or eliminate cancer outside the bone marro…
Phase 2 trial of BRIMOCHOL, BRIMOCHOL F, and carbachol for presbyopia completes with 18 subjects
Could new eye drops help you read without reading glasses?
A Phase 2, randomized, double-masked, crossover study evaluated BRIMOCHOL, BRIMOCHOL F, and carbachol monotherapy in 18 subjects with emmetr…
New eye drops aim to let people read menus and texts clearly without losing distance vision, offering a potential fix for age-related blurry…
Phase 2 trial of neoadjuvant/adjuvant pembrolizumab in stage IB-IIIA NSCLC completes enrollment of 35 patients
Can immunotherapy before lung cancer surgery help the immune system fight the tumor?
A multi-institutional phase 2 trial has completed enrollment of 35 patients to study neoadjuvant and adjuvant pembrolizumab in stage IB, II,…
Doctors tested giving immunotherapy before lung cancer surgery to see if it safely boosts the immune system's ability to fight the tumor.
MT-2301 Hib vaccine candidate shows efficacy in phase 2 study of 154 infants
How well does a new Hib vaccine protect infants when given with other routine shots?
A phase 2 study evaluated the efficacy and safety of MT-2301 (Haemophilus b conjugate vaccine) co-administered with DPT-IPV in healthy infan…
A new Hib vaccine given with routine shots reached the same antibody protection levels as the current approved vaccine in healthy infants.
Sentinel lymph node technique assessed in multifocal breast cancer (n=216)
Can doctors find the first lymph node cancer might reach in women with multiple breast tumors?
A phase 2 trial assessed the sentinel lymph node technique in 216 patients with multifocal breast cancer. The technique involved subareolar …
Doctors successfully mapped the first lymph node cancer reaches in women with multiple breast tumors using a safe dye and tracer injection t…
Phase II trial compares quizartinib vs placebo with chemotherapy in FLT3 wild-type AML
Can adding quizartinib to standard chemo help adults with a common type of acute myeloid leukemia?
A randomized phase II trial compared standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in 273 adults with new…
Adding quizartinib to standard chemotherapy for newly diagnosed acute myeloid leukemia aims to help patients live longer without their cance…
Daratumumab + Len/Dex shows ORR in relapsed/refractory multiple myeloma phase 1/2 trial
Can a new drug combination help people with multiple myeloma that has returned after treatment?
This phase 1/2 study evaluated daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed-refracto…
A new three-drug combination of daratumumab, lenalidomide, and dexamasone showed safety and response in people with relapsed multiple myelom…
VALIANT: Phase 2 trial of verekitug (UPB-101) for severe asthma completes enrollment of 479 patients
Can a new injection help people with severe asthma breathe easier and avoid dangerous flare-ups?
The VALIANT study, a phase 2 trial, evaluated the efficacy and safety of subcutaneous verekitug (UPB-101) versus placebo in adults with seve…
A new asthma injection aims to reduce dangerous flare-ups and improve breathing for adults with severe asthma in a completed trial.
Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma
Can a new drug help people with a rare eye cancer live longer?
This Phase II study evaluated IMCgp100 versus investigator's choice (dacarbazine, ipilimumab, or pembrolizumab) in HLA-A*0201 positive adult…
A new drug for advanced eye cancer is being compared to standard treatments to see if it helps patients with a specific genetic marker live …
Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28
Could a new psoriasis treatment work better by targeting two inflammation sources at once?
A Phase 2a, multicenter, randomized, subject- and investigator-blind study investigated the pharmacokinetics, pharmacodynamics, and safety o…
A new psoriasis drug targets two inflammation sources to see if it works better for thick, scaly skin patches in adults.
Phase IIb trial of HH-003 injection for chronic HDV infection completes enrollment of 101 patients
Could a new antibody treatment help people with a serious liver infection?
A multicenter, randomized, controlled, open-label Phase IIb study assessed the efficacy and safety of HH-003 injection in subjects with chro…
A new antibody injection helped control a serious liver virus and heal inflammation in patients with chronic hepatitis delta infection.
Phase 1b/2 study of ERAS-007 combinations in advanced GI malignancies completes enrollment of 101 patients
Can a new drug combination help people with advanced colorectal or pancreatic cancer?
A Phase 1b/2 platform study evaluated ERAS-007 in combination with other cancer therapies in patients with advanced gastrointestinal maligna…
A new drug combination tested in advanced colorectal and pancreatic cancer aims to find safe doses and early signs of tumor shrinkage in pat…
Phase 2 trial tests metformin with neoadjuvant radiochemotherapy for locally advanced rectal cancer
Could a common diabetes drug help people with rectal cancer respond better to treatment?
A Phase 2 trial (n=60) evaluated adding metformin to neoadjuvant radiochemotherapy (capecitabine + 50 Gy radiation) for locally advanced rec…
Adding a common diabetes pill to pre-surgery treatment for rectal cancer may help clear out cancer cells before the operation begins.
LSD Microdosing Shows Mood Improvement in Major Depressive Disorder: Phase 2a Trial
Can microdosing LSD really boost mood in people with depression?
An open-label trial of microdosed LSD in major depressive disorder showed mood improvements on dosing days (p = 0.009 to 0.039) but no chang…
People with depression taking microdosed LSD for eight weeks reported feeling happier and more creative on dosing days while symptoms droppe…
Phase II Study on SHR-8068 Injection in Colorectal Cancer Now Recruiting
Could a new treatment help fight colorectal cancer more effectively?
A Phase II trial is recruiting to assess SHR-8068 with Adebrelimab and Bevacizumab in colorectal cancer for pCR and PFS.
A new drug combo for colorectal cancer is being tested in 200 patients to see if it improves survival and tumor response.
Phase 2 Trial: SHR-1701 Plus Chemoradiotherapy for Advanced Rectal Cancer
Could a new drug boost treatment for severe colorectal cancer?
A Phase 2 trial is recruiting to evaluate SHR-1701 with chemoradiotherapy in severe CRC. Primary outcome is pCR.
A new drug combined with standard chemo and radiation aims to clear severe colorectal cancer before surgery in an upcoming trial.
Phase 2b Study Evaluates KT-621 for Eosinophilic Asthma
Can KT-621 help people with severe asthma breathe easier?
A Phase 2b trial is assessing KT-621's efficacy and safety in 264 adults with moderate to severe eosinophilic asthma.
A new drug called KT-621 is being tested to help people with uncontrolled moderate to severe eosinophilic asthma breathe easier by improving…
Phase 2 Study Evaluates Brenipatide for Moderate-to-Severe Asthma
Could a new drug help people with severe asthma breathe easier?
A Phase 2 trial is assessing the safety and efficacy of brenipatide versus placebo in 531 participants with moderate-to-severe asthma. The p…
A new asthma drug trial aims to reduce flare-ups and improve breathing for adults with moderate-to-severe asthma over the next year.
Study Validates Genotype Predictor of TIPN in African American Breast Cancer Patients
Could your genes predict nerve pain from breast cancer treatment?
This phase II trial with 249 participants evaluates a germline predictor of taxane-induced peripheral neuropathy (TIPN) in African American …
A genetic marker may predict severe nerve pain from breast cancer chemo in African American patients, with docetaxel possibly causing fewer …
Phase 2 Study Evaluates Abatacept for Kidney Transplant Recipients
Could a new biomarker improve kidney transplant outcomes for patients?
A Phase 2 study is recruiting 800 kidney transplant recipients to assess HLA-DR/DQ mMM scores as prognostic biomarkers. A nested RCT will ev…
A new kidney transplant biomarker could predict complications, while a follow-up trial tests if switching to abatacept improves function and…
Phase 2 Trial: Cytisine and ASA for Inflammation in Lifelong Smokers
Can quitting smoking and changing your diet really reduce lung inflammation?
A Phase 2 trial evaluates cytisine for smoking cessation and ASA for inflammation in 2000 lifelong smokers.
Quitting smoking, eating better, and moving more can reduce lung inflammation in lifelong smokers, offering a path to breathe easier and low…
Phase II Trial Explores Serplulimab and Chemoradiotherapy for GEJ Adenocarcinoma
Can a new treatment approach improve outcomes for patients with advanced stomach cancer?
A phase II trial investigates serplulimab with mSOX and radiotherapy in 48 patients with cStage III GEJ adenocarcinoma.
A new trial combines immunotherapy, chemotherapy, and radiation to clear advanced stomach cancer before surgery, aiming for no surviving cel…
Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients
Could Targeted Radiation Therapy Offer Hope for Lung Cancer Patients?
This Phase 2 trial evaluates the addition of liver stereotactic ablative radiotherapy (L-SABR) to standard drug therapy in metastatic NSCLC.…
A new trial tests if adding targeted liver radiation to standard drugs helps metastatic lung cancer patients live longer without disease pro…
Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma
Could This New Drug Offer Hope for Patients with Returning Pleural Mesothelioma?
A Phase II trial evaluates ivonescimab in 38 pleural mesothelioma patients post-immunotherapy/chemotherapy. The study aims for a ≥55% diseas…
Patients with returning pleural mesothelioma may find hope in ivonescimab, a new drug being tested to control stubborn cancer after standard…
Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD
Could New Treatments Help Those Struggling with Kidney Disease?
A Phase 2a trial is assessing frexalimab, brivekimig, and rilzabrutinib for reducing proteinuria in FSGS and MCD. Primary outcome is the per…
New kidney treatments aim to reduce urine protein and improve daily life for patients with FSGS or minimal change disease.
Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria
Could a New Drug Offer Hope for Kidney Disease Sufferers?
A Phase 2 trial is evaluating ManNAc for primary FSGS in 30 patients. Primary endpoints include proteinuria reduction and safety. Results pe…
A new drug called ManNAc may help reduce protein loss in urine for people with kidney scarring, offering hope for those facing dialysis or t…
Phase 2 Trial Evaluates mRNA Influenza Vaccines' Safety and Immunogenicity in Adults
Could This New Vaccine Help Us Finally Beat the Flu?
This Phase 2 trial investigates the safety and immunogenicity of five mRNA-based influenza vaccines in 770 healthy adults. Primary outcomes …
Pfizer is testing new mRNA flu vaccines in healthy adults to see if they trigger a stronger immune response and reduce flu complications bet…
Dasatinib and Quercetin Show Promise in Improving Gait Speed in HIV-Associated Frailty
Can a New Drug Combination Help Older Adults with HIV Regain Strength?
Phase II trial of dasatinib and quercetin (D+Q) in 82 HIV+ frail/prefrail adults shows potential in improving gait speed. Primary endpoint: …
A new trial tests if two drugs help older adults with HIV regain strength and walk better after years of frailty.
RAD51-foci Score Predicts Olaparib Efficacy in Advanced HER2-negative Breast Cancer
Could a Simple Test Help Tailor Breast Cancer Treatment?
Phase II study shows RAD51-foci score predicts olaparib response in BRCA1/2, PALB2, RAD51C/D mutated breast cancer. Study enrolled 65 patien…
A new test may help doctors choose the right drug sooner for women with advanced breast cancer who have specific genetic mutations.
Phase 1/2 Study of Dual-Target CAR-NK Cells in Recurrent Ovarian Cancer
Could New Cell Therapy Change the Game for Women with Recurrent Ovarian Cancer?
This Phase 1/2 trial assesses the safety and preliminary efficacy of dual-target CAR-NK cells in recurrent ovarian cancer, focusing on dose-…
Women with recurrent ovarian cancer may find new hope in a trial testing dual-target CAR-NK cells designed to attack tumors that resist stan…
Phase 2 Study of BGB-16673 in B-Cell Malignancies: Safety and Dose Findings
Could This New Drug Offer Hope for Patients with Tough Blood Cancers?
This ongoing Phase 1/2 trial evaluates BGB-16673 in B-cell malignancies, focusing on safety and dose determination. Primary outcomes include…
Patients with tough B-cell blood cancers may find a new option in the drug BGB-16673, currently being tested to find the right safe dose and…
Phase II Trial: HST-NEETs Shows Promise in HIV-Associated Lymphoma Post-ASCT
Can a New Treatment Help Patients with HIV-Related Lymphoma Beat the Odds?
In a Phase II trial, HST-NEETs were administered post-ASCT in 12 patients with HIV-associated lymphoma. The study aimed to assess the feasib…
A new treatment combining immune therapy and bone marrow transplant aims to help patients with HIV-related lymphoma receive care sooner afte…
Phase II Trial Explores Nivolumab in High-Risk HIV-Associated Anal Cancer
Can New Treatments Help Fight HIV-Related Anal Cancer More Effectively?
This Phase II trial investigates the safety of reduced intensity CRT in low-risk HIV-associated anal cancer and nivolumab post-CRT in high-r…
A new trial tests gentler radiation and chemotherapy for low-risk HIV anal cancer, while adding immunotherapy for high-risk cases to improve…
Phase 2 Trial of Icalcaprant for MDD: Assessing Efficacy and Safety
Could This New Drug Help Ease Severe Depression Symptoms?
A Phase 2 trial is evaluating the efficacy and safety of oral Icalcaprant in 195 adults with MDD. Primary outcomes include changes in MADRS …
A new drug called Icalcaprant is being tested to see if it can help adults with major depressive disorder who are currently experiencing a m…
LP-184 Alone and With Spironolactone in Recurrent Glioblastoma: Phase 1a Results
New drug combo may help brain cancer patients who have run out of options
This Phase 1a trial in 63 patients (16 with glioblastoma) found LP-184 was well tolerated but with more transaminitis and thrombocytopenia i…
A new drug combination could help brain cancer patients by making their current medicine work much harder inside the tumor.
MCH1 Receptor Antagonist RGH-706 Shows Weight Loss in Preclinical and Early Clinical Study
New Drug Targets Hunger Brain Signals to Help Shed Pounds
A preclinical and phase I/II study evaluated the MCH1 receptor antagonist RGH-706 for obesity and Prader-Willi Syndrome. In diet-induced obe…
Scientists found a new medicine that may help people lose weight by turning off hunger signals.
Donor-derived anti-CD33 CAR T-cell therapy showed 20% overall response in 15 adults with relapsed AML/MDS.
Donor-Derived Cells Show Promise Against Leukemia Relapse
This Phase 1/2 study enrolled 15 adults with relapsed or MRD-positive CD33+ AML/MDS after allogeneic hematopoietic cell transplantation. Don…
A new treatment using donor immune cells shows early signs of fighting leukemia after transplant.
RADAR pipeline identifies 20 high-confidence retired antigen candidates from 4,664 initial candidates.
Computers Find Safe Targets for New Cancer Vaccines
This Phase 1 computational pipeline development study utilized an in silico analysis of 4,664 initial candidates derived from GTEx. The RADA…
Imagine a protein that your body ignores when you are healthy but attacks when cells turn cancerous.
Etalanetug reduces CSF tau biomarkers in dominantly inherited Alzheimer's disease in phase 1b/2 study.
Can a new drug slow Alzheimer's toxic tau protein in the brain?
This open-label phase 1b/2 study in 8 participants with mild-to-moderate cognitive impairment due to dominantly inherited Alzheimer's diseas…
An early study shows an experimental drug lowers two key tau proteins in spinal fluid for people with a rare inherited form of Alzheimer's.
Camonsertib plus gemcitabine shows preliminary activity in advanced solid tumors with DDR alterations
New Drug Combo Helps Some Solid Tumors Grow Slower
This Phase Ib trial evaluated camonsertib plus gemcitabine in 76 patients with advanced solid tumors harboring DDR gene alterations. Tumor r…
This combination might offer a new hope for patients whose tumors have stopped responding to standard treatments.
Phase 1 trial of oral ASTX727 plus talazoparib in previously treated triple-negative metastatic breast cancer patients.
New Drug Combo Stops Breast Cancer Growth
This Phase 1 study enrolled 34 evaluable patients with previously treated triple-negative, hormone-resistant, or HER2-negative metastatic br…
This new combination may help some patients keep their cancer stable for months when other options have run out.
Posdinemab shows linear pharmacokinetics and predicted tau reduction in Phase 1 AD study
New Alzheimer's Drug Could Silence Brain's Toxic Tangles
This Phase 1 mechanistic population pharmacokinetic-pharmacodynamic model evaluated posdinemab in 69 healthy adults and participants with Al…
A new Alzheimer's drug could silence toxic brain tangles before memory loss worsens, offering hope for millions of families facing early-sta…
Lirafugratinib sequencing with futibatinib shows feasibility in FGFR2-driven cancers based on early-phase trial data
Can a new cancer drug work better if you switch to another drug after it stops?
This Phase I/II preprint trial evaluated lirafugratinib in 30 patients with FGFR2-driven cancers, including intrahepatic cholangiocarcinoma.…
When a cancer drug stops working, switching to a different one might help because the two medicines attack the disease in slightly different…
HS-20093 shows response in lung cancers in Phase 1a/b trial
New Drug Targets Deadly Lung Cancer Cells
A Phase 1a/b trial in 306 patients with previously treated advanced solid tumors found HS-20093, a B7-H3-targeted antibody-drug conjugate, h…
A new drug attacks a specific protein on lung cancer cells, helping more than half of patients with an aggressive type while remaining safe …
Early study of CDP1 plus chemotherapy showed promising activity and manageable safety in advanced penile cancer.
New Drug Combo Shrinks Advanced Penile Cancer Tumors
This prospective phase 1 study evaluated the safety and antitumor activity of CDP1 monotherapy or in combination with standard chemotherapy …
A new drug combo shrinks advanced penile cancer tumors, offering fresh hope for patients with rare, hard-to-treat disease.
Pirtobrutinib shows activity in relapsed and refractory marginal zone lymphoma patients in a Phase 1/2 trial.
Early trial shows pirtobrutinib helped some patients with relapsed marginal zone lymphoma.
This Phase 1/2 trial evaluated pirtobrutinib in 36 patients with relapsed and refractory marginal zone lymphoma. The investigator-assessed o…
A new drug helped more than half of patients with relapsed lymphoma shrink their tumors, offering hope for those who have run out of other t…
Phase 1b ABBV-368 combinations in recurrent/metastatic HNSCC show 14.3% overall response rate
Early study of ABBV-368 plus other drugs showed limited tumor response in head and neck cancer patients.
This phase 1b, multicenter, open-label study enrolled 30 adults with recurrent or metastatic head and neck squamous cell carcinoma across th…
Early trials of ABBV-368 combined with other drugs showed limited tumor shrinkage in head and neck cancer patients despite a generally safe …
Izalontamab brengitecan shows activity in pretreated NSCLC with non-classical actionable genomic alterations
For lung cancer patients who have run out of options, a new drug mix shows promise but needs more time.
This phase 1 study evaluated izalontamab brengitecan (iza-bren) in 83 patients with locally advanced or metastatic NSCLC harboring actionabl…
Lung cancer patients with limited options saw tumors shrink in 40% of cases and disease controlled in 86% using a new drug mix with manageab…
TQB2618 plus penpulimab shows 52% response in PD-1 refractory Hodgkin lymphoma
A New Drug Duo Revives Hope for Hodgkin Lymphoma After Immunotherapy Fails
A phase Ib single-arm trial in 21 Chinese patients with PD-1/PD-L1 inhibitor-refractory classic Hodgkin lymphoma found TQB2618 plus penpulim…
A new two-drug combination revived hope for Hodgkin lymphoma patients who failed prior immunotherapy, achieving a 52% response rate in early…
Setidegrasib shows antitumor activity in advanced NSCLC and pancreatic cancer with p.G12D variants.
A Drug That Shreds a Famous Cancer Target
This Phase 1 study evaluated setidegrasib in 203 patients with previously treated advanced solid tumors harboring p.G12D variants. The drug …
A first-of-its-kind drug called setidegrasib shrank lung and pancreatic tumors in patients with a cancer mutation that has frustrated drugma…
Single-dose fultagliptin benzoate pharmacokinetics and safety in patients with mild to moderate renal insufficiency versus healthy volunteers
A New Diabetes Pill That Stays Longer When Kidneys Slow
This Phase I, non-randomized, open-label, parallel-control trial evaluated the pharmacokinetics, pharmacodynamics, and safety of a single or…
A new diabetes pill builds up in the body when kidneys slow, meaning some patients with mild or moderate kidney issues may need half the usu…
Phase I trial of regorafenib plus ipilimumab and nivolumab shows 27.6% response in MSS colorectal cancer
Who Really Responds to a Stubborn Colon Cancer Combo?
A phase I trial in 29 patients with microsatellite-stable metastatic colorectal cancer tested the combination of regorafenib, ipilimumab, an…
A three-drug combo helped some patients with stubborn colon cancer, and immune markers now predict who will benefit most.
Phase 1 trial of zamtocabtagene autoleucel shows 75% response in relapsed/refractory B-cell NHL
Can a new cell therapy help lymphoma patients who have run out of options?
A Phase 1 clinical trial in 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma evaluated zamtocabtagene autoleucel at two d…
Five of 12 lymphoma patients treated with a new cell therapy achieved complete remission with no cancer return after five years and no sever…
Ga-PSMA-11 PET/CT shows high sensitivity for local prostate cancer but lower for lymph nodes in phase 1/2 trial.
Imaging test shows promise for detecting prostate cancer spread in early trial
A prospective phase 1/2 single-arm trial in 173 high-risk prostate cancer patients found Ga-PSMA-11 PET/CT had 0.971 sensitivity for local d…
A new imaging test found prostate cancer in lymph nodes for 56% of patients, leading doctors to cancel surgery for 13% and adjust radiation …
CD19/BCMA CAR-T cells show early signal in six patients with refractory generalized myasthenia gravis
A One-Time Treatment Lets Patients with Severe Muscle Disease Stop Their Steroids
A Phase 1 study of 6 patients with refractory generalized myasthenia gravis found autologous CD19/BCMA CAR-T cells without prior lymphodeple…
A one-time infusion of engineered immune cells allowed patients with a debilitating muscle-weakening disease to stop steroids and live sympt…
Phase Ib/II trial of nintedanib plus nivolumab in pretreated NSCLC adenocarcinoma shows 25% 6-month PFS rate
New Drug Combo Helps Some Lung Cancer Patients Live Longer
A single-arm, open-label phase Ib/II trial in 52 patients with pretreated stage IIIB/IV NSCLC adenocarcinoma found a 6-month progression-fre…
A new drug pair safely extends life for some advanced lung cancer patients who previously tried immunotherapy or have high PD-L1 markers.
Phase 1/2 trial shows RT + bevacizumab + olaptesed pegol extends PFS and OS in unmethylated GBM
New Drug Combo Slows Brain Cancer Growth
A Phase 1/2 expansion arm in six patients with newly-diagnosed, unmethylated GBM found that adding bevacizumab to radiotherapy and olaptesed…
Adding a second drug to stop blood vessel growth gives patients with brain cancer more time before the disease returns.
Phase 1 trial of off-the-shelf NK cell therapy shows no DLTs or responses in relapsed/refractory AML
A Safer, Ready-to-Use Cell Therapy Takes Aim at Tough Leukemia
A single-arm, open-label, dose-escalation Phase 1 trial enrolled 6 adults with relapsed/refractory AML who received SAR445419, an off-the-sh…
A new, ready-to-use cell therapy proved safe in a first human trial for aggressive leukemia, offering hope for patients who have run out of …
Mitoxantrone liposome plus CMOP shows high response rates in untreated peripheral T-cell lymphoma patients.
New Drug Combo Helps Most Patients With Hard-to-Treat Lymphoma
This phase 1b multicenter clinical trial evaluated mitoxantrone hydrochloride liposome combined with cyclophosphamide, vincristine, and pred…
A new drug combo wrapped in fat bubbles helped 89% of patients with hard-to-treat lymphoma shrink tumors without causing deaths.
Phase 1 trial shows feasibility of 3D CRT plus SBRT boost for metastatic spinal cord compression
Adding a second radiation boost helps spinal cord patients
A Phase 1 clinical trial in 13 patients with metastatic epidural spinal cord compression (MESCC) found the combined 3D CRT and SBRT boost re…
A second, highly targeted radiation treatment helps people with spinal cord compression move better and feel less pain without causing new n…
Reni-cel gene therapy shows transfusion independence in small phase 1-2 trial for β-thalassemia
New Gene Edit Stops Blood Transfusions
A single-group phase 1-2 trial in 9 adults with transfusion-dependent β-thalassemia found all participants achieved neutrophil engraftment a…
A new gene edit reactivates natural red blood cell production, potentially ending the need for lifelong transfusions in adults with severe b…
Renizgamglogene autotemcel infusion showed engraftment and hemoglobin increases in severe sickle cell disease patients.
One Gene Edit Stopped Painful Sickle Cell Crises in Most Patients
This single-group, open-label, multicenter Phase 1-2 trial enrolled 28 patients with severe sickle cell disease aged 12 to 50 years. Followi…
A single infusion of CRISPR-edited stem cells eliminated painful sickle cell crises in 27 out of 28 patients by switching the body back to p…
Anti-BCMA CAR T-cell therapy bb21217 with bb007 showed 69.4% response in relapsed multiple myeloma.
Memory Cells Make CAR T Last Longer
This Phase I study evaluated anti-B-cell maturation antigen CAR T-cell therapy bb21217 manufactured with the phosphoinositide 3-kinase inhib…
CAR T cells trained to act like long-term guards may keep multiple myeloma away for years instead of burning out quickly after initial treat…
Linvoseltamab shows improved outcomes versus real-world standard of care in relapsed/refractory multiple myeloma
New Hope for Myeloma Patients After Three Failed Treatments
A Phase 1/2 study with an external control arm compared linvoseltamab to real-world standard of care in 105 triple-class exposed or refracto…
Patients with multiple myeloma who failed three prior treatments show higher response rates and longer survival with linvoseltamab compared …
Pivekimab sunirine shows activity in frontline and relapsed Blastic plasmacytoid dendritic cell neoplasm.
A New Drug Shows Striking Promise for a Rare and Aggressive Blood Cancer
This phase I/II single-arm trial evaluated pivekimab sunirine in adults with Blastic plasmacytoid dendritic cell neoplasm (BPDCN). In the pr…
For a cancer with very few options, this therapy is changing the outlook for patients and creating a clear path to potentially curative stem…
First-in-human study finds VS-01 generally well tolerated in decompensated cirrhosis with ascites
Early safety study of VS-01 infusion in 12 patients with advanced liver disease
This phase 1b, open-label, non-randomized study in 12 patients with decompensated cirrhosis, ascites, and covert hepatic encephalopathy foun…
A new liver treatment called VS-01 was safe for patients with advanced disease, causing mostly mild stomach issues in an early study of 12 p…
Phase Ib trial: Mam-A DNA vaccine plus endocrine therapy induces T cells in ER+ breast cancer
Can a breast cancer vaccine help the immune system target tumors?
A phase Ib clinical trial in 21 patients with estrogen receptor-positive breast cancer prior to surgery found that adding Mammaglobin-A DNA …
A breast cancer vaccine triggered specific immune cells to attack tumors in early trial patients, showing promising biological activity befo…
Pilot nationwide carrier screening in Singapore identifies 0.9% of couples at increased risk
Singapore pilot program screens couples for genetic disease risk, finds 0.9% at higher risk
A pilot implementation study of a nationwide reproductive carrier screening program in Singapore, using a 112-gene panel, found 0.9% of 456 …
Singapore's new genetic screening program found 0.9% of couples carry risks for recessive diseases, sparking interest and support for expand…
Novel TWISTARE MRI technique shows potential for faster quantitative T2 brain mapping in preclinical validation
New MRI technique shows promise for faster, precise brain tissue mapping in lab tests
A preclinical validation study of the TWISTARE MRI technique for quantitative T2 and B1 mapping at 7T demonstrated high precision in phantom…
A new MRI technique called TWISTARE could cut scan time in half while keeping brain tissue maps just as precise as current methods.
Firmonertinib plus anlotinib shows preliminary efficacy in advanced EGFR-mutant NSCLC.
Early trial shows firmonertinib plus anlotinib helps some advanced lung cancer patients
This single-arm, phase I/II trial evaluated firmonertinib combined with anlotinib in patients with advanced non-small cell lung cancer (NSCL…
Combining firmonertinib and anlotinib helped 64% of advanced lung cancer patients shrink tumors and keep disease controlled for over a year …
Subcutaneous amivantamab shows shorter administration time and fewer infusion reactions in advanced solid tumors
Could a simple injection replace hours-long cancer infusions?
A phase Ib clinical trial in 158 patients with advanced solid malignancies evaluated subcutaneous amivantamab administration. Compared to hi…
A new injection method for advanced cancer treatment cuts administration time to under 10 minutes and reduces severe side effects compared t…
Phase I study finds amrubicin-cisplatin with radiotherapy feasible in limited-stage SCLC
Small study tests new drug combination with radiation for limited-stage small cell lung cancer
A Phase I dose-finding trial in 9 treatment-naïve patients with limited-stage small cell lung cancer established amrubicin 25 mg/m² plus cis…
A new drug combination with radiation showed a 100% response rate and 64.8% five-year survival in early-stage small cell lung cancer patient…
Phase 1 study finds molnupiravir 800 mg well-tolerated with no NHC accumulation in healthy Chinese adults
How does a COVID-19 pill behave in the body? A small study in healthy men offers clues.
An open-label, fixed-sequence Phase 1 study in 16 healthy male Chinese adults evaluated the pharmacokinetics and safety of oral molnupiravir…
Understanding how a drug moves through the body is a crucial first step. A small, early study in healthy Chinese men found the active part o…
SMART radiation shows 90% 4-year local control in small oligometastatic abdominopelvic cohort
Can targeted radiation safely treat small, recurring cancer spots in the abdomen?
A single-arm Phase 1/2 trial in 10 patients with solid tumor abdominopelvic oligometastases found Stereotactic MR-Guided Adaptive Radiation …
Targeted radiation safely controlled small recurring cancer spots in the abdomen for 90% of patients with only mild side effects after four …
Fulzerasib plus cetuximab shows 69% response in first-line KRAS-mutated NSCLC
Can a new drug combination shrink lung tumors in people with a specific KRAS mutation?
A single-arm phase 1b/2 trial in 47 treatment-naive patients with KRAS-mutated NSCLC found a confirmed objective response rate of 69% (90% C…
A new two-drug combination shrank tumors in nearly 70% of people with advanced lung cancer driven by a specific genetic mutation.
Lu-PSMA-617 plus pembrolizumab shows PSA response in mCRPC phase 1b/2 trial
Can a new drug combo help men with advanced prostate cancer?
In a single-arm phase 1b/2 trial of 37 patients with mCRPC, Lu-PSMA-617 plus pembrolizumab achieved a 50% PSA decline in 28 participants (76…
A new drug combo helped 28 of 37 men with advanced prostate cancer cut their PSA levels in half while keeping side effects mostly mild to mo…
Ifinatamab deruxtecan shows antitumor activity in advanced treatment-refractory solid tumors in phase 1/2 trial
Early trial shows experimental drug shrinks tumors in some patients with advanced cancers
This first-in-human phase 1/2 trial of 97 patients with advanced treatment-refractory solid tumors found a confirmed objective response rate…
An early trial of a new experimental drug shrank tumors in 34% of patients with advanced cancers that had stopped responding to standard tre…
Phase 1b trial finds tafasitamab combinations manageable in Japanese B-cell NHL patients
Early study tests tafasitamab alone and in combinations for Japanese lymphoma patients
A phase 1b trial in 24 Japanese patients with relapsed/refractory or untreated B-cell NHL assessed tafasitamab alone or in combination. All …
Japanese lymphoma patients received new drug tafasitamab alone or with others, showing manageable side effects like low blood counts and nau…
Phase 1 trial of WVT078 with/without WHG626 shows preliminary activity in relapsed/refractory multiple myeloma
Can a new combination therapy help when multiple myeloma returns?
A phase 1 dose-escalation trial in 56 patients with relapsed/refractory multiple myeloma assessed the BCMA×CD3 bispecific antibody WVT078 al…
Adding a second drug to a new antibody therapy nearly doubled response rates in early trials for patients with returning multiple myeloma.
Modeling study predicts human pharmacokinetics for TAK-500, an anti-CCR2 antibody-drug conjugate
Early modeling study predicts how a new cancer drug candidate might behave in humans
A preclinical and clinical modeling study used cynomolgus monkey data and human parental antibody data to simulate human pharmacokinetics fo…
A computer model predicts that a new cancer drug stays in the body longer as the dose increases, helping scientists plan safe first-in-human…
Prime editing therapy shows early neutrophil activity in two patients with p47-deficient CGD
Early trial shows gene editing therapy may restore immune function in two patients with rare disease
A Phase 1 trial in two participants with p47-deficient chronic granulomatous disease (CGD) found that autologous CD34+ cell therapy using pr…
Two patients with a rare immune disorder regained the ability to fight infections after receiving a new gene editing therapy that fixed thei…
AAV9 gene therapy shows biochemical improvement, stable motor scores in GM1 gangliosidosis phase 1-2 trial
Can gene therapy slow a rare, fatal childhood brain disease? Early trial shows some signs it might.
In a phase 1-2 trial of nine children with type II GM1 gangliosidosis, a single IV infusion of AAV9 encoding β-galactosidase increased CSF β…
A rare fatal childhood brain disease showed signs of slowing in an early trial where gene therapy reduced toxic buildup and stabilized some …
FMT + Nivolumab Shows 20% ORR in 10 ICI-Refractory GI Cancer Patients
Could a gut bacteria transplant help when immunotherapy stops working for stomach cancer?
A phase I study in 10 patients with anti-PD-(L)1-refractory GI cancers found the combination of fecal microbiota transplantation (FMT) and n…
When stomach cancer resists standard immunotherapy, a gut bacteria transplant combined with treatment helped tumors shrink in two patients a…